Mortality among people who inject drugs: a systematic review and 
meta-analysis 
Bradley M Mathers,a Louisa Degenhardt,b Chiara Bucello,b James Lemon,b Lucas Wiessing c & Mathew Hickman d 

People who use drugs, especially by injection, are at higher 
risk of dying from both acute and chronic diseases, many of 
which are related to their drug use, than people who do not 
use these drugs. Fatal overdose and infection with human im- 
munodeficiency virus (HIV) and other blood-borne viruses 
transmitted through shared needles and syringes are the most 
common causes of death in this group.1 Understanding causes 
of death is important when setting priorities for programmes 
designed to reduce deaths from the use of drugs. Longitudinal 
studies of people who inject drugs are critical for assessing 
the magnitude, nature and correlates of the risk of death in 
this population. 
A systematic review conducted in 2004 identified 30 pro- 
spective studies published between 1967 and 2004 that dealt 
with “problematic drug users” or people who inject drugs.2 
These reviews have consistently shown that the practice of 
injecting drugs is associated with an elevated risk of death, 
particularly from the complications of HIV infection, drug 
overdose and suicide. Since these reviews were conducted, 
the number of studies examining mortality among cohorts 
of people who inject drugs has risen substantially. This has 
made it possible to perform fine-grained analyses that were not 
feasible in earlier reviews. Furthermore, those earlier reviews 
did not examine the potential impact of study-level variables, 
variation across countries, or of participant-level variables that 
could affect both mortality rates and differences in causes of 
death, yet study-level evidence suggests that males who inject 
drugs may be at higher risk of dying than females and that 
different types of drugs are associated with different risks of 
death.3–5 Findings from other reviews have also suggested that 
rates of death among people who are dependent on opioids are 
different from the rates of death observed in people who are 
dependent on stimulants such as cocaine and amphetamine 
type stimulants.3–5 
In recent years the number of studies reporting on mor- 
tality among people who inject drugs has increased. Hence, 
the objective of this review was to determine the following: 
• overall crude mortality rates (CMRs) and excess deaths 

• causes of death across studies, particularly from drug over- 
dose and acquired immunodeficiency syndrome (AIDS); 
differences in mortality rates and causes of death among 
HIV-positive (HIV+) and HIV-negative (HIV−) people 
who inject drugs; 






Methods 
Identifying studies 
A recent series of reviews identified cohort studies among opi- 
oid, amphetamine and cocaine users to examine mortality.3–5 In 
these reviews tailored search strings were used to search three 
electronic databases for studies published between 1980 and 
a The Kirby Institute, University of New South Wales, Sydney, NSW 2052, Australia. 
b National Drug and Alcohol Research Centre, University of New South Wales, Sydney, Australia. 
c Scientific Division, European Monitoring Centre for Drugs and Drug Addiction, Lisbon, Portugal. 
d School of Social and Community Medicine, University of Bristol, Bristol, England. 
Correspondence to Bradley M Mathers (e-mail: bmathers@kirby.unsw.edu.au). 
(Submitted: 31 May 2012 – Revised version received: 26 November 2012 – Accepted: 28 November 2012 ) 


Objective To systematically review cohort studies of mortality among people who inject drugs, examine mortality rates and causes of 
death in this group, and identify participant- and study-level variables associated with a higher risk of death. 
Methods Tailored search strings were used to search EMBASE, Medline and PsycINFO. The grey literature was identified through online 
grey literature databases. Experts were consulted to obtain additional studies and data. Random effects meta-analyses were performed to 
estimate pooled crude mortality rates (CMRs) and standardized mortality ratios (SMRs). 
Findings Sixty-seven cohorts of people who inject drugs were identified, 14 of them from low- and middle-income countries. The pooled 
CMR was 2.35 deaths per 100 person–years (95% confidence interval, CI: 2.12–2.58). SMRs were reported for 32 cohorts; the pooled SMR was 
14.68 (95% CI: 13.01–16.35). Comparison of CMRs and the calculation of CMR ratios revealed mortality to be higher in low- and middle-income 
country cohorts, males and people who injected drugs that were positive for human immunodeficiency virus (HIV). It was also higher during 
off-treatment periods. Drug overdose and acquired immunodeficiency syndrome (AIDS) were the primary causes of death across cohorts. 
Conclusion Compared with the general population, people who inject drugs have an elevated risk of death, although mortality rates vary 
across different settings. Any comprehensive approach to improving health outcomes in this group must include efforts to reduce HIV 
infection as well as other causes of death, particularly drug overdose. 



Systematic reviews 
Mortality among people who inject drugs 
2012: Medline, EMBASE and PsycINFO. 
The search strings contained keywords 
and database-specific terms (MeSH 
headings, EMTREE terms and explode 
terms; Box 1). All results were limited 
to human subjects. We identified grey 
literature sources reporting on mortality 
by searching online grey literature data- 
bases, library databases and the web sites 
listed in a published technical report.6 To 
make sure that no relevant papers had 
been missed, we sent the draft lists of the 
papers identified through these searches 
to experts for their review. 
For the current study we exam- 
ined all papers found in the reviews of 
drug-related mortality but selected only 
cohorts composed of people who in- 
jected opioids and other drugs. We used 
the strategy outlined in the preceding 
paragraph to further search for these 
cohorts. We included in the analysis 
only studies of drug users that included 
mortality data disaggregated by partici- 
pants’ injecting drug use; studies were 
included only if more than 70% of the 
cohort was composed of people who 
injected drugs. 
The searches yielded a total of 5981 
studies of mortality related to the use of 
opioids, amphetamines and cocaine. We 
identified another 79 articles by search- 
ing the reference lists of reviews on mor- 
tality related to drug use. Experts pro- 
vided additional studies for 16 cohorts. 
From these 5981 articles we excluded a 
total of 5762: 4999 did not focus on drug 
dependence or mortality, 118 did not 
include raw data, 292 were case series, 
and 600 had insufficient mortality data 
on people who inject drugs. In total, we 
selected 67 cohort studies for inclusion 
in the analyses (Fig. 1). These studies 
were further assessed using STROBE 
reporting guidelines.7 

Once we had identified all studies, one 
of the authors (JL) extracted the data 
into an Excel database (Microsoft, Red- 
mond, United States of America) and 
two others rechecked them (BM, CB). 
This yielded the basic data set for the 
statistical analyses. We extracted infor- 
mation on the location of each study, the 
period of recruitment and duration of 
follow-up, the number of people in the 
cohort, the percentage of people in the 
cohort who injected drugs, the number 
of person–years (PY) of follow-up and 
the number of deaths. 
We extracted CMRs and standard- 
ized mortality ratios (SMRs). We ex- 




Database specific search terms were developed and combined using Boolean operators as follows: 
( < opioids > OR < cocaine > OR < amphetamine type stimulants > ) AND < drug use > AND < mortality > AND < longitudinal studies > 
All results were limited to human subjects and publication years between 1980 and 2012. The full search strings used for each database were as follows: 
Medline: ((heroin or opiate$ OR opium OR opioid$ OR Exp Opium/ OR exp Narcotics/ OR exp Heroin Dependence/ OR exp Heroin/ OR exp 
Morphine/ OR exp Opioid-Related Disorders/ OR exp Opiate Alkaloids/ OR exp Methadone/ OR exp Analgesics, Opioid/) OR (Cocaine exp Cocaine- 
Related Disorders/ or exp Cocaine/ or exp Crack Cocaine/) OR (ATS OR amphetamine type stimulant$ OR amphetamine$ OR methamphetamine OR 
deoxyephedrine OR desoxyephedrine OR Desoxyn OR madrine OR metamfetamine OR methamphetamine hydrochloride OR methylamphetamine 
OR n-methylamphetamine OR d-amphetamine OR dextroamphetamine sulfate OR dexamphetamine OR dexedrine OR dextro-amphetamine sulfate 
OR dextroamphetamine sulfate OR d-amphetamine sulfate OR stimulant$ exp amphetamines/ or exp amphetamine/ or exp dextroamphetamine/ 
or exp p-chloroamphetamine/ or exp 2,5-dimethoxy-4-methylamphetamine/ or exp p-hydroxyamphetamine/ or exp iofetamine/ or exp 
methamphetamine/ or exp benzphetamine/ or exp phentermine/ or exp chlorphentermine/ or exp mephentermine/ or exp amphetamine-related 
disorders/)) AND (drug abuse$ OR drug use$ OR drug misuse$ OR drug dependenc$ OR substance abuse$ OR substance use$ OR substance misuse$ 
OR substance dependenc$ OR addict$ OR Exp Substance-related disorders/) AND (Mortal$ OR fatal$ OR death$ OR exp “death and dying”/ OR exp 
mortality/ OR exp hospitalization) AND (“cohort” OR “longitudinal” OR “incidence” OR “prospective” OR “follow-up” OR exp cohort studies/ OR exp 
longitudinal studies/ OR exp follow-up studies/ OR exp prospective studies/) 
EMBASE: ((heroin OR opioid$ OR opiate$ OR opium OR exp Diamorphine/ OR exp Opiate/ OR exp Methadone treatment/ OR exp Methadone/) OR 
(Cocaine exp Cocaine-Related Disorders/ or exp Cocaine/ or exp Crack Cocaine/) OR (ATS OR amphetamine type stimulant$ OR amphetamine$ OR 
methamphetamine OR deoxyephedrine OR desoxyephedrine OR Desoxyn OR madrine OR metamfetamine OR methamphetamine hydrochloride 
OR methylamphetamine OR n-methylamphetamine OR d-amphetamine OR dextroamphetamine sulfate OR dexamphetamine OR dexedrine OR 
dextro-amphetamine sulfate OR dextroamphetamine sulfate OR d-amphetamine sulfate OR stimulant$ exp amphetamines/ or exp amphetamine/ 
or exp dextroamphetamine/ or exp p-chloroamphetamine/ or exp 2,5-dimethoxy-4-methylamphetamine/ or exp p-hydroxyamphetamine/ or 
exp iofetamine/ or exp methamphetamine/ or exp benzphetamine/ or exp phentermine/ or exp chlorphentermine/ or exp mephentermine/ or 
exp amphetamine-related disorders/)) AND (Drug abuse OR drug use$ OR drug misuse OR drug dependenc$ OR substance abuse OR substance 
use$ OR substance misuse OR substance dependenc$ OR addict$ OR exp substance abuse/ OR exp drug abuse/ OR exp analgesic agent abuse/ 
OR exp drug abuse pattern/ OR exp drug misuse/ OR exp drug traffic/ OR exp multiple drug abuse/ OR exp addiction/ OR exp drug dependence/ 
OR exp cocaine dependence/ OR narcotic dependence/ OR exp heroin dependence/ OR exp morphine addiction/ OR exp opiate addiction/) AND 
(Mortal$ OR fatal$ OR death$ OR exp death/ OR exp “cause of death”/ OR exp accidental death/ OR exp sudden death/ OR exp fatality/ OR exp 
mortality/ OR exp hospitalization/) AND (“cohort” OR “longitudinal” OR “incidence” OR “prospective” OR “follow-up” OR exp cohort analysis/ OR exp 
longitudinal study/ OR exp prospective study/ OR exp follow up/) 
PsychINFO: ((“heroin” OR “opium” OR “opiate$” OR “methadone” OR exp Opiates/ OR exp METHADONE/ OR exp HEROIN ADDICTION/ OR exp HEROIN) 
OR (Cocaine exp Cocaine-Related Disorders/ or exp Cocaine/ or exp Crack Cocaine/) OR (ATS OR amphetamine type stimulant$ OR amphetamine$ 
OR methamphetamine OR deoxyephedrine OR desoxyephedrine OR Desoxyn OR madrine OR metamfetamine OR methamphetamine hydrochloride 
OR methylamphetamine OR n-methylamphetamine OR d-amphetamine OR dextroamphetamine sulfate OR dexamphetamine OR dexedrine OR 
dextro-amphetamine sulfate OR dextroamphetamine sulfate OR d-amphetamine sulfate OR stimulant$ exp amphetamines/ or exp amphetamine/ 
or exp dextroamphetamine/ or exp p-chloroamphetamine/ or exp 2,5-dimethoxy-4-methylamphetamine/ or exp p-hydroxyamphetamine/ or 
exp iofetamine/ or exp methamphetamine/ or exp benzphetamine/ or exp phentermine/ or exp chlorphentermine/ or exp mephentermine/ or 
exp amphetamine-related disorders/)) AND (Drug abuse OR drug use$ OR drug misuse OR drug dependenc$ OR substance abuse OR substance 
use$ OR substance misuse OR substance dependenc$ OR addict$ OR Exp drug abuse/ OR exp drug addiction/ OR exp addiction/ OR exp drug 
usage) AND (Mortal$ OR fatal$ OR death$ OR exp “death and dying”/ OR exp mortality/ OR exp hospitalization) AND (“cohort” OR “longitudinal” OR 
“incidence” OR “prospective” OR “follow-up” OR Exp age differences/ OR exp cohort analysis/ OR exp human sex differences) 
Systematic reviews 
Mortality among people who inject drugs 




levels of heterogeneity between stud- 
ies because of the marked differences 
between the samples of people inject- 
ing drugs; accordingly, we applied a 
random effects model to all analyses. 
The appropriateness of this a priori 
decision was confirmed by the resultant 
χ2 and the I-squared statistic. To further 
investigate this heterogeneity, when the 
data permitted we divided the cohorts 
into subgroups and used CMR ratios to 
compare differences in mortality.11 We 
made comparisons between subgroups 
as follows: sex (male versus female); pri- 
mary drug injected at baseline (opioids 
versus stimulants); HIV status (HIV+ 
versus HIV−); and treatment for drug 
dependence (in-treatment period versus 
off-treatment period). 
We examined the following as po- 
tential sources of heterogeneity in CMRs 
or SMRs using random effects univariate 
meta-regressions in STATA: geographic 
region, country income group (based on 
World Bank categories), percentage of 
sample that injected drugs, were male 
or were HIV+ at baseline; presence of 
opioid users in the cohort; and the year 
in which the follow-up period ended.12,13 
We included 67 cohorts in the analysis; 
14 were from low- and middle-income 
countries (Table 1). Studies from Eu- 
rope, North America and Australasia 
were the most common; nine studies 
were from Asia and one was from South 
America. The pooled CMR across the 65 
cohorts for which a CMR was provided 
was 2.35 deaths per 100 PY (Fig. 2). Co- 
horts from Asia had the highest pooled 
CMRs (5.25), followed by the cohorts 
from North America (2.64) and western 
Europe (2.31); cohorts from Australasia 
had the lowest pooled CMR (0.71). 
SMRs were reported for 31 cohorts; 
their pooled SMR was 14.68 (Fig. 3). 
Since the heterogeneities (I2) of the 
pooled CMR and SMR were both very 
high (98.6% and 98.3%, respectively), we 
stratified estimates by subgroups. 

Thirty-seven studies presented CMRs 
by s e x . 1 4 , 1 7 – 1 9 , 2 1 – 2 4 , 2 6 , 2 8 , 3 0 – 3 2 , 3 4 , 3 6 – 3 8 , 4 3 , 
45–50,52,54,57,58,62,66–72,74 The pooled CMR 
ratio for males versus females was 1.32 
(Fig. 4), which suggests that crude mor- 
tality was higher among males. Nineteen 
studies reported SMRs by sex;14,17,21,24, 
26,28,30,32,34,38,43,46,52,54,58,66,67,70,74 the pooled 
pressed CMRs as the number of deaths 
per 100 PY of follow-up. We reported 
SMRs as calculated in the source pa- 
pers. In several cases standard errors, 
confidence intervals (CIs) and CMRs 
were not reported, so we estimated them 
using standard calculations. We also put 
into the database CMRs and SMRs that 
were reported according to sex, HIV 
status, treatment status and type of drug 
injected, as well as data on deaths from 
drug overdose or AIDs-related causes. 
We included in the analyses studies 
that specified treatment status if they 
classified the data by mutually exclusive 
treatment groups or periods. We only 
included studies in which the exact dates 
of entry into and exit from the study had 
been recorded and used to calculate the 
number of PYs, the number of deaths 
and mortality rates. 
Statistical analysis 
We performed meta-analyses to estimate 
pooled all-cause CMRs and all-cause 
SMRs, and pooled estimates of deaths 
from specific causes, as in previous re- 
views.8 To perform the meta-analyses we 
used the “metan” command in STATA 
version 10.1 (StataCorp LP, College Sta- 
tion, USA). The “metan” command uses 
inverse-variance weighting to calculate 
random effects pooled summary esti- 
mates and their confidence limits, true 
effect differences between studies and 
study heterogeneity.9,10 Random effects 
models allow for heterogeneity between 
and within studies. We expected high 


Total from 
initial search 
Hand search: 
79 
From experts: 
16 
Not drug/mortality focused: 
4999 
No raw data: 
118 
Case series studies: 
292 
Insufficient mortality data on people 
 who inject drugs: 600 








Systematic reviews 
Mortality among people who inject drugs 



























































Systematic reviews 
Mortality among people who inject drugs 




























































Systematic reviews 
Mortality among people who inject drugs 




















Systematic reviews 
Mortality among people who inject drugs 








Image produced using Stata (StataCorp. LP, College Station, TX, United States of America). 
CI, confidence interval; CMR, crude mortality rate. 



Western Europe 
Antolini 2006 (Italy) 
Bargagli 2001 (Italy) 
Bauer 2008 (Austria) 
Brancato 1995 (Italy) 
Ciccolallo 2000 (Italy) 
Clausen 2008 (Norway) 
Copeland 2004 (UK) 
Cornish 2010 (UK) 
Davoli 2007 (Italy) 
EMCDDA 2011 (Sweden) 
Eskild 1993 (Norway) 
Esteban 2003 (Spain) 
Frischer 1997 (UK) 
Fugelstad 1995 (Sweden) 
Fugelstad 1997 (Sweden) 
Fugelstad 1998 (Sweden) 
Galli 1994 (Italy) 
Goedert 1995 (Italy) 
Golz 2001 (Germany) 
Haarr 2007 (Norway) 
Hickman 2003 (UK) 
Jarrin 2007 (Spain) 
Lejckova 2007 (Czech Republic) 
Lumbreras 2006 (Spain) 
Manfredi 2006 (Italy) 
Mezzelani 1998 (Italy) 
Moroni 1991 (Italy) 
Muga 2007 (Spain) 
Nyhlen 2011 (Sweden) 
Oppenheimer 1994 (UK) 
Sanchez−Carbonell 2000 (Spain) 
Seaman 1998 (UK) 
Sorensen 2005 (Denmark) 
Stenbacka 2007 (Sweden) 
VanHaastrecht 1996 (Netherlands) 
Zabransky 2011 (Czech Republic) 
Zaccarelli 1994 (Italy) 
Subtotal (I−squared = 97.4%, p = 0.000) 
. 
Asia 
Azim 2008 (Bangladesh) 
Azim 2009 (Bangladesh) 
Jafan 2010 (Islamic Republic of Iran) 
Liu 2011 (China) 
Quan 2007 (Thailand) 
Quan 2010 (Viet Nam) 
Rahimi-Movahgar 2009 (Islamic Republic of Iran) 
Solomon 2009 (India) 
Zhang 2005 (China) 
Subtotal (I−squared = 74.3%, p = 0.000) 
. 
Latin America 
Cardoso 2006 (Brazil) 
Subtotal (I−squared = .%, p = .) 
. 
Australasia 
Degenhardt 2009 (Australia) 
Digusto 2004 (Australia) 
Reece 2010 (Australia) 
Stoove 2008 (Australia) 
Tait 2008 (Australia) 
Subtotal (I−squared = 89.7%, p = 0.000) 
. 
Eastern Europe 
EMCDDA 2011 (Romania) 
EMCDDA 2011 (Croatia) 
EMCDDA 2011 (Bulgaria) 
EMCDDA 2011 (Latvia) 
Moskalewicz 1996 (Poland) 
Subtotal (I−squared = 97.1%, p = 0.000) 
. 
North America 
Evans 2012 (USA) 
Fingerhood 2006 (USA) 
Goedert 2001 (USA) 
McAnulty 1995 (USA) 
Miller 2007 (Canada) 
O’Driscoll 2001 (USA) 
Vlahov 2005 (USA) 
Vlahov 2008 (USA) 
Subtotal (I−squared = 99.4%, p = 0.000) 
. 
Overall (I−squared = 98.6%, p = 0.000) 

CMR (95% CI) 
CMR (95% CI) 
% 
% 
Weight 
2.01 (1.79, 2.16) 
2.01 (1.79, 2.16) 
2.15 (2.05, 2.25) 
2.15 (2.05, 2.25) 
5.42 (3.45, 7.40) 
5.42 (3.45, 7.40) 
2.04 (1.26, 2.83) 
2.04 (1.26, 2.83) 
2.26 (2.08, 2.43) 
2.26 (2.08, 2.43) 
1.95 (1.70, 2.23) 
1.95 (1.70, 2.23) 
2.45 (2.06, 2.84) 
2.45 (2.06, 2.84) 
1.00 (0.86, 1.15) 
1.00 (0.86, 1.15) 
0.74 (0.59, 0.88) 
0.74 (0.59, 0.88) 
3.33 (2.98, 3.68) 
3.33 (2.98, 3.68) 
2.77 (2.22, 3.42) 
2.77 (2.22, 3.42) 
3.68 (3.11, 4.25) 
3.68 (3.11, 4.25) 
2.08 (1.52, 2.64) 
2.08 (1.52, 2.64) 
3.85 (2.94, 4.76) 
3.85 (2.94, 4.76) 
1.99 (1.72, 2.25) 
1.99 (1.72, 2.25) 
7.76 (5.54, 10.58) 
7.76 (5.54, 10.58) 
2.52 (2.28, 2.77) 
2.52 (2.28, 2.77) 
1.57 (1.41, 1.75) 
1.57 (1.41, 1.75) 
4.22 (2.80, 5.64) 
4.22 (2.80, 5.64) 
1.92 (0.95, 3.44) 
1.92 (0.95, 3.44) 
1.61 (1.13, 2.23) 
1.61 (1.13, 2.23) 
2.02 (1.92, 2.12) 
2.02 (1.92, 2.12) 
0.84 (0.75, 0.93) 
0.84 (0.75, 0.93) 
2.18 (2.00, 2.36) 
2.18 (2.00, 2.36) 
2.04 (1.80, 2.30) 
2.04 (1.80, 2.30) 
2.91 (2.48, 3.33) 
2.91 (2.48, 3.33) 
2.43 (2.16, 2.69) 
2.43 (2.16, 2.69) 
3.74 (3.38, 4.14) 
3.74 (3.38, 4.14) 
1.30 (1.12, 1.48) 
1.30 (1.12, 1.48) 
1.83 (1.28, 2.38) 
1.83 (1.28, 2.38) 
3.40 (2.36, 4.44) 
3.40 (2.36, 4.44) 
2.33 (1.60, 3.27) 
2.33 (1.60, 3.27) 
3.49 (2.45, 4.53) 
3.49 (2.45, 4.53) 
2.12 (1.93, 2.31) 
2.12 (1.93, 2.31) 
3.23 (2.56, 4.07) 
3.23 (2.56, 4.07) 
0.48 (0.15, 0.81) 
0.48 (0.15, 0.81) 
2.30 (1.96, 2.63) 
2.30 (1.96, 2.63) 
2.31 (2.06, 2.56) 
2.31 (2.06, 2.56) 
6.32 (4.68, 7.96) 
6.32 (4.68, 7.96) 
3.52 (2.46, 4.59) 
3.52 (2.46, 4.59) 
4.08 (1.25, 6.91) 
4.08 (1.25, 6.91) 
6.89 (5.79, 7.98) 
6.89 (5.79, 7.98) 
3.85 (2.42, 5.83) 
3.85 (2.42, 5.83) 
6.30 (4.60, 8.50) 
6.30 (4.60, 8.50) 
4.83 (0.00, 14.30) 
4.83 (0.00, 14.30) 
4.25 (3.35, 5.16) 
4.25 (3.35, 5.16) 
7.73 (4.87, 10.60) 
7.73 (4.87, 10.60) 
5.25 (4.16, 6.35) 
5.25 (4.16, 6.35) 
2.77 (1.45, 4.09) 
2.77 (1.45, 4.09) 
2.77 (1.45, 4.09) 
2.77 (1.45, 4.09) 
0.89 (0.86, 0.92) 
0.89 (0.86, 0.92) 
1.27 (0.40, 2.29) 
1.27 (0.40, 2.29) 
0.50 (0.36, 0.65) 
0.50 (0.36, 0.65) 
0.83 (0.56, 1.21) 
0.83 (0.56, 1.21) 
0.50 (0.29, 0.72) 
0.50 (0.29, 0.72) 
0.71 (0.46, 0.96) 
0.71 (0.46, 0.96) 
0.57 (0.47, 0.68) 
0.57 (0.47, 0.68) 
1.09 (0.93, 1.25) 
1.09 (0.93, 1.25) 
1.18 (0.91, 1.46) 
1.18 (0.91, 1.46) 
1.60 (1.43, 1.77) 
1.60 (1.43, 1.77) 
2.28 (1.81, 2.83) 
2.28 (1.81, 2.83) 
1.31 (0.82, 1.80) 
1.31 (0.82, 1.80) 
0.91 (0.62, 1.20) 
0.91 (0.62, 1.20) 
7.14 (5.22, 9.06) 
7.14 (5.22, 9.06) 
4.67 (4.42, 4.92) 
4.67 (4.42, 4.92) 
1.05 (0.69, 1.41) 
1.05 (0.69, 1.41) 
1.37 (0.80, 1.94) 
1.37 (0.80, 1.94) 
1.59 (1.22, 1.96) 
1.59 (1.22, 1.96) 
4.50 (4.24, 4.76) 
4.50 (4.24, 4.76) 
0.71 (0.54, 0.88) 
0.71 (0.54, 0.88) 
2.64 (1.25, 4.02) 
2.64 (1.25, 4.02) 
1.83 
1.83 
1.84 
1.84 
0.77 
0.77 
1.51 
1.51 
1.83 
1.83 
1.80 
1.80 
1.75 
1.75 
1.83 
1.83 
1.83 
1.83 
1.77 
1.77 
1.64 
1.64 
1.66 
1.66 
1.66 
1.66 
1.43 
1.43 
1.80 
1.80 
0.57 
0.57 
1.81 
1.81 
1.83 
1.83 
1.08 
1.08 
1.19 
1.19 
1.67 
1.67 
1.84 
1.84 
1.84 
1.84 
1.83 
1.83 
1.81 
1.81 
1.74 
1.74 
1.80 
1.80 
1.76 
1.76 
1.83 
1.83 
1.67 
1.67 
1.33 
1.33 
1.48 
1.48 
1.33 
1.33 
1.82 
1.82 
1.54 
1.54 
1.78 
1.78 
1.78 
1.78 
60.26 
60.26 
0.94 
0.94 
1.31 
1.31 
0.48 
0.48 
1.29 
1.29 
0.91 
0.91 
0.78 
0.78 
0.10 
0.10 
1.43 
1.43 
0.47 
0.47 
7.71 
7.71 
1.14 
1.14 
1.14 
1.14 
1.85 
1.85 
1.40 
1.40 
1.83 
1.83 
1.78 
1.78 
1.82 
1.82 
8.68 
8.68 
1.84 
1.84 
1.83 
1.83 
1.80 
1.80 
1.83 
1.83 
1.69 
1.69 
8.99 
8.99 
1.79 
1.79 
0.80 
0.80 
1.81 
1.81 
1.77 
1.77 
1.65 
1.65 
1.76 
1.76 
1.80 
1.80 
1.83 
1.83 
13.22 
13.22 
2.35 (2.12, 2.58) 
2.35 (2.12, 2.58) 
100.00 
100.00 
 
 

Systematic reviews 
Mortality among people who inject drugs 

Image produced using Stata (StataCorp. LP, College Station, TX, United States of America). 
CI, confidence interval; SMR, standardized mortality ratio. 


0 

CMR ratio suggests that females had 
significantly greater excess mortality 
than males in similar age groups in the 
general population (Fig. 5). Only two 
of the nineteen studies presented SMRs 
for males that were greater than those 
for females.30,74 

Several studies reported specific causes 
of death. The pooled CMR for death 
from drug overdose was 0.62 per 100 PY 
across 43 studies (Fig. 6). Eleven stud- 
ies reported CMRs for death from drug 
overdose by sex: overall the CMR was 
1.38 times higher (Fig. 7) among males 
than among females.14,17,19,21,24,32,38,49,52,57,58 
In 20 studies CMRs were pro- 
vided separately for people who inject 
drugs according to their HIV sta- 
tus.15,16,18,28,34,36–40,45,48,49,55,57,60,65,70,72,74 All- 
cause mortality was three times higher 
among HIV+ than among HIV− sub- 
jects (CMR ratio: 3.15) (Fig. 8). Much 
of this elevated mortality appeared 
to result from AIDS deaths among 
HIV+ users of injecting drugs. The 
pooled estimate of AIDS-related mor- 
tality for the 16 studies for which data 
were available was 2.55 per 100 PY 
(Fig. 9).28,33–36,38–41,48,49,60,65,70,72,74 When 
we examined mortality from causes 
other than AIDS, we found it to be 
1.63 times higher among HIV+ than 
among HIV− people who inject drugs 
(Fig. 10).28,34,36,38–40,48,49,60,65,70,72,74 
Mortality from drug overdose was 
presented by HIV status in 9 stud- 
ies.28,34,36,38,39,49,65,70,74 Pooled estimates 
showed mortality to be twice as high 
among HIV+ than among HIV− people 
who inject drugs (CMR ratio: 1.99) 
(Fig. 11). Further analyses across 13 
studies conducted on HIV+ people 
who inject drugs showed no significant 



Western Europe 
Antolini 2006 (Italy) 
Bargagli 2001 (Italy) 
Bauer 2008 (Austria) 
Ciccolallo 2000 (Italy) 
Copeland 2004 (UK) 
EMCDDA 2011 (Sweden) 
Eskild 1993 (Norway) 
Ferri 2007 (Italy) 
Frischer 1997 (UK) 
Galli 1994 (Italy) 
Lejckova 2007 (Czech Republic) 
Mezzelani 1998 (Italy) 
Nyhlen 2011 (Sweden) 
Oppenheimer 1994 (UK) 
Sanchez−Carbonell 2000 (Spain) 
Sorensen 2005 (Denmark) 
Stenbacka 2007 (Sweden) 
VanHaastrecht 1996 (Netherlands) 
Zabransky 2011 (Czech Republic) 
Zaccarelli 1994 (Italy) 
Subtotal (I−squared = 98.8%, p = 0.000) 
. 
Asia 
Quan 2007 (Thailand) 
Quan 2010 (Viet Nam) 
Solomon 2009 (India) 
Zhang 2005 (China) 
Subtotal (I−squared = 81.2%, p = 0.001) 
. 
Australasia 
Degenhardt 2009 (Australia) 
Subtotal (I−squared = .%, p = .) 
. 
Eastern Europe 
EMCDDA 2011 (Romania) 
EMCDDA 2011 (Croatia) 
EMCDDA 2011 (Latvia) 
Moskalewicz 1996 (Poland) 
Subtotal (I−squared = 87.7%, p = 0.000) 
. 
North America 
McAnulty 1995 (USA) 
Miller 2007 (Canada) 
Subtotal (I−squared = 64.4%, p = 0.094) 
. 
Overall (I−squared = 98.3%, p = 0.000) 

SMR (95% CI) 

% 
Weight 

13.01 (11.38, 13.09) 

17.30 (16.50, 18.20) 

29.13 (19.27, 44.04) 

30.70 (17.30, 44.00) 

17.45 (14.59, 20.30) 

27.60 (24.90, 30.70) 

31.00 (24.60, 37.40) 

7.77 (6.70, 8.95) 

22.00 (16.50, 28.80) 

20.50 (20.02, 24.33) 

8.15 (7.28, 9.09) 

14.28 (12.28, 16.56) 

5.94 (5.50, 6.80) 

11.90 (8.64, 16.09) 

28.58 (14.65, 42.65) 

15.75 (11.40, 21.20) 

4.38 (3.99, 4.78) 

24.80 (19.41, 31.23) 

14.40 (9.31, 19.49) 

31.92 (27.44, 36.93) 

17.52 (14.62, 20.43) 

13.90 (8.71, 21.04) 

13.40 (11.40, 15.30) 

11.10 (8.85, 13.70) 

47.62 (31.63, 68.71) 

14.47 (9.95, 19.00) 

6.40 (6.20, 6.60) 

6.40 (6.20, 6.60) 

6.50 (5.40, 7.70) 

10.30 (8.90, 12.00) 

9.00 (8.00, 10.00) 

12.06 (9.60, 15.00) 

9.25 (7.22, 11.28) 

8.30 (5.71, 11.66) 

16.40 (9.10, 27.10) 

11.19 (3.58, 18.80) 

4.08 

4.08 

1.26 

1.13 

3.68 

3.67 

2.57 

4.05 

2.65 

3.86 

4.08 

3.86 

4.10 

3.42 

1.06 

3.04 

4.12 

2.72 

2.98 

3.09 

63.51 

2.64 

3.91 

3.80 

0.68 

11.02 

4.12 

4.12 

4.05 

3.98 

4.07 

3.72 

15.82 

3.65 

1.88 

5.53 

14.68 (13.01, 16.35) 

100.00 

 
 
Systematic reviews 
Mortality among people who inject drugs 


Image produced using Stata (StataCorp. LP, College Station, TX, United States of America). 
CI, confidence interval; RR, relative risk. 





difference in deaths from drug overdose 
and from AIDS in this group (CMR 
ratio: 1.35; P = 0.554) (Fig. 12).28,33–36,38, 
39,41,49,65,70,71,74 
Only four studies presented data by 
sex and HIV status.37,47,49,74 They showed 
no significant difference in CMRs be- 
tween HIV+ males and HIV+ females 
who inject drugs (CMR ratio: 1.13; 
Fig. 13), but HIV– males had a pooled 
CMR 1.81 times greater than that of 
HIV– females who inject drugs (Fig. 14). 
Mortality by primary drug 
injected at baseline 
Five studies estimated mortality by 
primary drug injected (opioids versus 
stimulants) (Table 2). Pooled estimates 
of all-cause mortality by primary type 
of drug injected showed no overall dif- 
ference across studies (CMR ratio: 1.25; 
95% CI: 0.60–2.61; P = 0.553).36,46,57,70,71 
The same was true of studies of mortal- 
ity resulting from drug overdose (CMR 
ratio: 1.85; 95% CI: 0.75–4.56; P = 0.18). 
In three of the four studies mortality as- 
sociated with drug overdose was higher 
among people injecting opioids than 
among those injecting stimulants.36,46,71 
In the fourth study, people who injected 
primarily stimulants had higher rates of 
drug overdose; however, the deaths from 
overdose in this group were later shown to 
have been caused by opioid use.57 

Six studies provided information on 
mortality during in-treatment and 
off-treatment periods at follow-up: the 
meta-analysis suggested that mortality 
was 2.52 times higher during off-treat- 
ment periods than during in-treatment 
periods (Fig. 15).22,23,25,26,35,37 

We performed univariate analyses to 
determine if the heterogeneity in overall 
CMRs and SMRs could be explained by 
participant characteristics and method- 
ological variables. The results showed 
that high-income countries had lower 



Antolini 2006 (Italy) 
Bargagli 2001 (Italy) 
Bauer 2008 (Austria) 
Brancato 1995 (Italy) 
Ciccolallo 2000 (Italy) 
Clausen 2008 (Norway) 
Copeland 2004 (UK) 
Cornish 2010 (UK) 
Degenhardt 2009 (Australia) 
EMCDDA 2011 (Croatia) 
Eskild 1993 (Norway) 
Evans 2012 (USA) 
Ferri 2007 (Italy) 
Frischer 1997 (UK) 
Fugelstad 1997 (Sweden) 
Fugelstad 1998 (Sweden) 
Galli 1994 (Italy) 
Hickman 2003 (UK) 
Jarrin 2007 (Spain) 
Lejckova 2007 (Czech Republic) 
Liu 2011 (China) 
Lumbreras 2006 (Spain) 
Manfredi 2006 (Italy) 
McAnulty 1995 (USA) 
Miller 2007 (Canada) 
Moskalewicz 1996 (Poland) 
O’Driscoll 2001 (USA) 
Oppenheimer 1994 (UK) 
Reece 2010 (Australia) 
Sorensen 2005 (Denmark) 
Stenbacka 2007 (Sweden) 
Stoove 2008 (Australia) 
Tait 2008 (Australia) 
VanHaastrecht 1996 (Netherlands) 
Vlahov 2005 (USA) 
Vlahov 2008 (USA) 
Zaccarelli 1994 (Italy) 
Overall (I−squared = 63.9%, p = 0.000) 
RR (95% CI) 
RR (95% CI 
1.30 (1.09, 1.55) 
1.30 (1.09, 1.55) 
0.97 (0.86, 1.09) 
0.97 (0.86, 1.09) 
2.62 (1.18, 5.81) 
2.62 (1.18, 5.81) 
1.14 (0.44, 3.01) 
1.14 (0.44, 3.01) 
1.32 (1.09, 1.61) 
1.32 (1.09, 1.61) 
1.14 (0.85, 1.53) 
1.14 (0.85, 1.53) 
1.23 (0.87, 1.74) 
1.23 (0.87, 1.74) 
1.67 (1.16, 2.40) 
1.67 (1.16, 2.40) 
1.58 (1.47, 1.70) 
1.58 (1.47, 1.70) 
2.57 (1.56, 4.24) 
2.57 (1.56, 4.24) 
1.08 (0.70, 1.67) 
1.08 (0.70, 1.67) 
1.60 (0.76, 3.37) 
1.60 (0.76, 3.37) 
1.51 (1.06, 2.16) 
1.51 (1.06, 2.16) 
0.99 (0.57, 1.72) 
0.99 (0.57, 1.72) 
1.35 (0.99, 1.84) 
1.35 (0.99, 1.84) 
1.74 (0.93, 3.26) 
1.74 (0.93, 3.26) 
1.14 (0.89, 1.45) 
1.14 (0.89, 1.45) 
2.01 (0.78, 5.18) 
2.01 (0.78, 5.18) 
1.36 (1.19, 1.55) 
1.36 (1.19, 1.55) 
1.88 (1.44, 2.45) 
1.88 (1.44, 2.45) 
0.80 (0.39, 1.66) 
0.80 (0.39, 1.66) 
1.50 (1.21, 1.86) 
1.50 (1.21, 1.86) 
1.14 (0.86, 1.51) 
1.14 (0.86, 1.51) 
1.59 (0.66, 3.84) 
1.59 (0.66, 3.84) 
0.64 (0.27, 1.53) 
0.64 (0.27, 1.53) 
1.80 (1.00, 3.23) 
1.80 (1.00, 3.23) 
1.10 (0.68, 1.78) 
1.10 (0.68, 1.78) 
0.86 (0.45, 1.64) 
0.86 (0.45, 1.64) 
3.31 (1.31, 8.36) 
3.31 (1.31, 8.36) 
0.68 (0.37, 1.24) 
0.68 (0.37, 1.24) 
1.24 (0.98, 1.56) 
1.24 (0.98, 1.56) 
3.49 (1.32, 9.22) 
3.49 (1.32, 9.22) 
1.09 (0.43, 2.76) 
1.09 (0.43, 2.76) 
1.42 (0.87, 2.32) 
1.42 (0.87, 2.32) 
1.20 (1.04, 1.38) 
1.20 (1.04, 1.38) 
1.21 (0.73, 1.99) 
1.21 (0.73, 1.99) 
1.22 (0.86, 1.74) 
1.22 (0.86, 1.74) 
1.32 (1.21, 1.44) 
1.32 (1.21, 1.44) 
% 
% 
Weight 
4.98 
4.98 
5.63 
5.63 
1.01 
1.01 
0.72 
0.72 
4.76 
4.76 
3.68 
3.68 
3.13 
3.13 
2.99 
2.99 
6.03 
6.03 
2.05 
2.05 
2.44 
2.44 
1.12 
1.12 
3.06 
3.06 
1.77 
1.77 
3.52 
3.52 
1.48 
1.48 
4.19 
4.19 
0.75 
0.75 
5.50 
5.50 
3.95 
3.95 
1.17 
1.17 
4.56 
4.56 
3.77 
3.77 
0.85 
0.85 
0.88 
0.88 
1.63 
1.63 
2.15 
2.15 
1.41 
1.41 
0.77 
0.77 
1.58 
1.58 
4.35 
4.35 
0.71 
0.71 
0.77 
0.77 
2.11 
2.11 
5.39 
5.39 
2.04 
2.04 
3.09 
3.09 
100.00 
100.00 

 
 

Systematic reviews 
Mortality among people who inject drugs 

Image produced using Stata (StataCorp. LP, College Station, TX, United States of America). 
CI, confidence interval; RR, relative risk. 



CMRs than low- and middle-income 
countries (Fig. 16). Cohorts with greater 
proportions of males and HIV+ partici- 
pants at baseline also had higher CMRs. 
Cohorts whose follow-up periods ended 
in more recent years had lower SMRs 
(Table 3). Study data were not sufficient 
to allow for multivariate analyses. 

Although previous reviews have exam- 
ined mortality among people who inject 
drugs, to our knowledge this is the most 
comprehensive systematic review of 
the topic and the first to employ novel 
approaches to search for the available 
evidence. These approaches ranged from 
standard searches of the peer-reviewed 
literature to comprehensive searches of 
the non-peer reviewed literature and 
multiple expert consultations, as well 
as examination of both participant- and 
study-level factors potentially associated 
with the risk of death. 
The pooled CMR of 2.35 deaths 
per 100 PY provides evidence of the 
high mortality associated with injecting 
drug use. The pooled SMR of 14.68 also 
shows that mortality is much higher 
in those who inject drugs than in the 
general population. Differences by sex 
were evident: across all studies that 
reported mortality by sex, males had 
higher CMRs, yet females who inject 
drugs had a much higher elevation in 
mortality relative to their age-matched 
peers in the general population than did 
males who inject drugs. 
Most of the cohorts identified were 
from 14 high-income countries; togeth- 
er these 14 counties represent 78% of 
the total estimated population of people 
who inject drugs in such countries.76 
Studies from only 11 low or middle 
income countries were identified; these 
countries account for only 40% of the 
estimated number of people inject- 
ing drugs in low- or middle-income 
countries.76 
Although pooled CMRs were 
higher among people injecting drugs 
in low- and middle-income countries 
rather than high-income countries, we 
observed no significant difference in 
pooled SMRs. This suggests that the 
higher CMRs may reflect higher over- 
all mortality in the general population 
in low- and middle-income countries 
than in high-income countries. The 
lowest and highest mortality rates were 
documented in cohorts in Australasia 
and Asia, respectively. Differences across 
high-income countries probably reflect 
differences in HIV infection prevalence, 
coverage of HIV prevention and cov- 
erage of opioid agonist maintenance 
treatment.76,77 
Drug overdose and AIDS-related 
mortality were by far the most com- 
mon causes of death. The pooled CMR 
for death from drug overdose was 0.62 
per 100 PY, higher among males than 
females who inject drugs, and higher 
among HIV+ people who inject drugs 
than among those who were HIV−. 
In three of the four studies comparing 
drug overdose among people injecting 
opioids compared to those injecting 
stimulants, CMRs were higher among 
the former group, as expected.36,46,71 In 



























0.60 (0.50, 0.71) 
0.60 (0.50, 0.71) 
0.41 (0.36, 0.46) 
0.41 (0.36, 0.46) 
0.50 (0.41, 0.61) 
0.50 (0.41, 0.61) 
0.67 (0.47, 0.95) 
0.67 (0.47, 0.95) 
0.68 (0.63, 0.73) 
0.68 (0.63, 0.73) 
1.05 (0.64, 1.73) 
1.05 (0.64, 1.73) 
0.43 (0.28, 0.67) 
0.43 (0.28, 0.67) 
0.29 (0.21, 0.42) 
0.29 (0.21, 0.42) 
0.43 (0.25, 0.74) 
0.43 (0.25, 0.74) 
0.36 (0.28, 0.46) 
0.36 (0.28, 0.46) 
0.95 (0.37, 2.45) 
0.95 (0.37, 2.45) 
0.99 (0.76, 1.29) 
0.99 (0.76, 1.29) 
0.24 (0.10, 0.57) 
0.24 (0.10, 0.57) 
0.55 (0.31, 0.99) 
0.55 (0.31, 0.99) 
0.81 (0.42, 1.53) 
0.81 (0.42, 1.53) 
0.37 (0.20, 0.67) 
0.37 (0.20, 0.67) 
0.60 (0.47, 0.75) 
0.60 (0.47, 0.75) 
0.79 (0.49, 1.29) 
0.79 (0.49, 1.29) 
1.44 (1.01, 2.05) 
1.44 (1.01, 2.05) 
6.94 
6.94 
7.24 
7.24 
6.83 
6.83 
5.74 
5.74 
7.40 
7.40 
4.60 
4.60 
5.06 
5.06 
5.68 
5.68 
4.21 
4.21 
6.50 
6.50 
2.30 
2.30 
6.35 
6.35 
2.60 
2.60 
4.00 
4.00 
3.66 
3.66 
3.93 
3.93 
6.60 
6.60 
4.68 
4.68 
5.70 
5.70 
0.58 (0.49, 0.69) 
0.58 (0.49, 0.69) 
100.00 
100.00 
 
 
Systematic reviews 
Mortality among people who inject drugs 


Image produced using Stata (StataCorp. LP, College Station, TX, United States of America). 
CI, confidence interval; CMR, crude mortality rate. 


0 



a fourth study, however, drug overdose 
was higher among people who injected 
stimulants,57 although further inves- 
tigation revealed that the deaths from 
overdose in this group were more often 
linked to the injection of opioids than 
to the injection of stimulants. This find- 
ing highlights the fact that people who 
inject drugs often use more than one 
drug type, even if they have a particular 
drug of choice. 
The prevalence of HIV infection 
varied widely. As expected, overall mor- 
tality was much higher among HIV+ 
than among HIV− people who inject 
drugs (pooled CMR ratio: 3.15), but 
mortality from causes other than AIDS 
was also higher among those who were 
HIV+. Overdose-related mortality was 
also higher among HIV+ people who 
inject drugs in many cohorts. These 
differences in mortality may reflect dif- 
ferences in risky behaviour, physical 
health and social disadvantage. 
The observational evidence exam- 
ined in this review is consistent with the 
evidence from randomized controlled 
trials that opioid agonist maintenance 
treatment is associated with a reduced 
risk of death.78 Among cohorts for which 
in-treatment and off-treatment periods 
were carefully tracked, mortality rates 
were around 2.5 times higher in off- 
treatment periods than in in-treatment 
periods. Variation in exposure to treat- 
ment could also explain differences 
between cohorts in mortality from drug 
overdose, although this variation was 
not explicitly measured across cohorts. 
The prevention of HIV transmis- 
sion among people who inject drugs is 
clearly a public health priority.79,80 There 
is growing evidence that opioid agonist 
maintenance treatment, antiretrovi- 
ral treatment and needle and syringe 
programmes reduce HIV transmis- 
sion.81–83 These interventions have been 
implemented in many countries, but 



Antolini 2006 (Italy) 
Bargagli 2001 (Italy) 
Bauer 2008 (Austria) 
Brancato 1995 (Italy) 
Ciccolallo 2000 (Italy) 
Clausen 2008 (Norway) 
Copeland 2004 (UK) 
Davoli 2007 (Italy) 
Degenhardt 2009 (Australia) 
Digusto 2004 (Australia) 
Eskild 1993 (Norway) 
Ferri 2007 (Italy) 
Fingerhood 2006 (USA) 
Frischer 1997 (UK) 
Fugelstad 1995 (Sweden) 
Fugelstad 1997 (Sweden) 
Galli 1994 (Italy) 
Goedert 1995 (Italy) 
Goedert 2001 (USA) 
Haarr 2007 (Norway) 
Hickman 2003 (UK) 
Jarrin 2007 (Spain) 
Lejckova 2007 (Czech Republic) 
Manfredi 2006 (Italy) 
McAnulty 1995 (USA) 
Miller 2007 (Canada) 
Moroni 1991 (Italy) 
O’Driscoll 2001 (USA) 
Oppenheimer 1994 (UK) 
Quan 2007 (Thailand) 
Seaman 1998 (UK) 
Solomon 2009 (India) 
Stenbacka 2007 (Sweden) 
Stoove 2008 (Australia) 
Tait 2008 (Australia) 
van Haastrecht 1996 (Netherlands) 
Vlahov 2005 (USA) 
Vlahov 2008 (USA) 
Zaccarelli 1994 (Italy) 
Zhang 2005 (China) 
Nyhlen 2011 (Sweden) 
Zabransky 2011 (Czech Republic) 
Quan 2010 (Viet Nam) 
Overall (I−squared = 96.2%, p = 0.000) 
CMR (95% CI 
CMR (95% CI) 
0.61 (0.53, 0.69) 
0.61 (0.53, 0.69) 
0.52 (0.47, 0.57) 
0.52 (0.47, 0.57) 
2.06 (0.84, 3.27) 
2.06 (0.84, 3.27) 
0.80 (0.30, 1.30) 
0.80 (0.30, 1.30) 
0.69 (0.60, 0.80) 
0.69 (0.60, 0.80) 
1.03 (0.84, 1.22) 
1.03 (0.84, 1.22) 
0.61 (0.43, 0.83) 
0.61 (0.43, 0.83) 
0.40 (0.09, 0.72) 
0.40 (0.09, 0.72) 
0.43 (0.41, 0.45) 
0.43 (0.41, 0.45) 
0.76 (−0.10, 1.62) 
0.76 (−0.10, 1.62) 
1.85 (1.37, 2.33) 
1.85 (1.37, 2.33) 
0.46 (0.39, 0.56) 
0.46 (0.39, 0.56) 
0.81 (0.30, 1.76) 
0.81 (0.30, 1.76) 
0.98 (0.63, 1.45) 
0.98 (0.63, 1.45) 
2.30 (1.64, 3.10) 
2.30 (1.64, 3.10) 
0.97 (0.78, 1.15) 
0.97 (0.78, 1.15) 
0.92 (0.77, 1.07) 
0.92 (0.77, 1.07) 
0.30 (0.23, 0.37) 
0.30 (0.23, 0.37) 
0.64 (0.55, 0.74) 
0.64 (0.55, 0.74) 
1.22 (0.32, 2.12) 
1.22 (0.32, 2.12) 
1.01 (0.58, 1.44) 
1.01 (0.58, 1.44) 
0.32 (0.28, 0.36) 
0.32 (0.28, 0.36) 
0.18 (0.14, 0.23) 
0.18 (0.14, 0.23) 
0.45 (0.34, 0.56) 
0.45 (0.34, 0.56) 
0.41 (0.22, 0.71) 
0.41 (0.22, 0.71) 
0.25 (0.07, 0.64) 
0.25 (0.07, 0.64) 
0.93 (0.77, 1.12) 
0.93 (0.77, 1.12) 
0.70 (0.48, 0.98) 
0.70 (0.48, 0.98) 
0.77 (0.46, 1.22) 
0.77 (0.46, 1.22) 
0.89 (0.11, 1.67) 
0.89 (0.11, 1.67) 
1.41 (0.86, 2.18) 
1.41 (0.86, 2.18) 
1.10 (0.64, 1.56) 
1.10 (0.64, 1.56) 
0.05 (0.02, 0.08) 
0.05 (0.02, 0.08) 
0.44 (0.26, 0.75) 
0.44 (0.26, 0.75) 
0.14 (0.03, 0.26) 
0.14 (0.03, 0.26) 
0.72 (0.41, 1.17) 
0.72 (0.41, 1.17) 
0.71 (0.61, 0.82) 
0.71 (0.61, 0.82) 
0.31 (0.21, 0.46) 
0.31 (0.21, 0.46) 
0.55 (0.40, 0.74) 
0.55 (0.40, 0.74) 
4.71 (2.53, 6.88) 
4.71 (2.53, 6.88) 
0.30 (0.22, 0.39) 
0.30 (0.22, 0.39) 
0.12 (0.00, 0.29) 
0.12 (0.00, 0.29) 
1.69 (0.73, 2.65) 
1.69 (0.73, 2.65) 
0.62 (0.53, 0.70) 
0.62 (0.53, 0.70) 
% 
% 
Weight 
3.27 
3.27 
3.32 
3.32 
0.40 
0.40 
1.50 
1.50 
3.21 
3.21 
2.85 
2.85 
2.79 
2.79 
2.24 
2.24 
3.36 
3.36 
0.71 
0.71 
1.57 
1.57 
3.24 
3.24 
0.91 
0.91 
1.83 
1.83 
0.91 
0.91 
2.88 
2.88 
3.04 
3.04 
3.28 
3.28 
3.22 
3.22 
0.66 
0.66 
1.73 
1.73 
3.34 
3.34 
3.33 
3.33 
3.16 
3.16 
2.58 
2.58 
2.39 
2.39 
2.94 
2.94 
2.54 
2.54 
1.95 
1.95 
0.83 
0.83 
1.06 
1.06 
1.63 
1.63 
3.35 
3.35 
2.58 
2.58 
3.15 
3.15 
1.96 
1.96 
3.19 
3.19 
3.12 
3.12 
2.94 
2.94 
0.14 
0.14 
3.25 
3.25 
3.04 
3.04 
0.60 
0.60 
100.00 
100.00 

 
 

often on a limited scale only.77 Clearly, 
however, AIDS is only one of several 
common causes of death in this group: 
a comprehensive approach to improving 
health outcomes among people who 
inject drugs must also include efforts to 
reduce other causes of death frequently 
found among them, particularly drug 
overdose.84 

Evidence on mortality rates among users 
of injecting drugs is still predominantly 
from high-income countries, particu- 
larly in western Europe. Interestingly, 
however, this review has shown that 
despite marked differences in CMRs 
across countries, the extent to which 
this mortality exceeds that of the general 
population may show less pronounced 
differences. It would be inappropriate 
to assume that mortality is equally high 
among all people who inject drugs. New 
research in this area is needed, especially 
Systematic reviews 
Mortality among people who inject drugs 





Image produced using Stata (StataCorp. LP, College Station, TX, United States of America). 
CI, confidence interval, RR, relative risk. 

Image produced using Stata (StataCorp. LP, College Station, TX, United States of America). 
CI, confidence interval; HIV, human immunodeficiency virus; RR, relative risk. 






















1.83 (1.27, 2.64) 
1.83 (1.27, 2.64) 
15.22 
15.22 
1.41 (1.07, 1.85) 
1.41 (1.07, 1.85) 
17.94 
17.94 
0.63 (0.16, 2.40) 
0.63 (0.16, 2.40) 
2.82 
2.82 
1.84 (1.23, 2.74) 
1.84 (1.23, 2.74) 
14.29 
14.29 
1.05 (0.53, 2.08) 
1.05 (0.53, 2.08) 
8.16 
8.16 
0.65 (0.36, 1.17) 
0.65 (0.36, 1.17) 
9.88 
9.88 
1.03 (0.70, 1.54) 
1.03 (0.70, 1.54) 
14.32 
14.32 
3.00 (1.29, 6.97) 
3.00 (1.29, 6.97) 
6.07 
6.07 
3.36 (0.35, 32.19) 
3.36 (0.35, 32.19) 
1.08 
1.08 
1.49 (0.69, 3.22) 
1.49 (0.69, 3.22) 
6.94 
6.94 
1.91 (0.56, 6.59) 
1.91 (0.56, 6.59) 
3.27 
3.27 

1.38 (1.08, 1.76 
1.38 (1.08, 1.76) 
100.00 
100.00 


























4.08 (2.26, 7.38) 

0.42 (0.06, 3.02) 

3.31 (1.63, 6.70) 

2.24 (1.46, 3.43) 

3.53 (1.55, 8.05) 
3.75 (2.84, 4.95) 
3.75 (2.84, 4.95) 

1.38 (0.74, 2.57) 

2.41 (1.98, 2.94) 

10.00 (5.59, 17.88) 

3.47 (3.11, 3.86) 

3.35 (3.00, 3.75) 

3.02 (2.54, 3.60) 

2.18 (1.58, 2.99) 

2.91 (2.24, 3.77) 

2.48 (0.92, 6.67) 

3.56 (2.04, 6.21) 

2.93 (1.94, 4.44) 

3.62 (2.27, 5.79) 

2.46 (1.18, 5.12) 

5.31 (3.75, 7.53) 


3.23 
3.23 
0.40 
0.40 
2.50 
2.50 
4.86 
4.86 
1.96 
1.96 

7.08 
3.00 
3.00 
8.50 
8.50 
3.32 
3.32 
9.92 
9.92 
9.85 
9.85 
8.89 
8.89 
6.42 
6.42 
7.41 
7.41 
1.44 
1.44 
3.52 
3.52 
5.01 
5.01 
4.37 
4.37 
2.36 
2.36 
5.95 
5.95 
3.15 (2.78, 3.58) 
3.15 (2.78, 3.58) 

100.00 
 
 
 
 
Systematic reviews 
Mortality among people who inject drugs 


Image produced using Stata (StataCorp. LP, College Station, TX, United States of America). 
AIDS, acquired immunodeficiency syndrome; CI, confidence interval; CMR, crude mortality rate; HIV, human immunodeficiency virus. 


0 








Image produced using Stata (StataCorp. LP, College Station, TX, United States of America). 
AIDS, acquired immunodeficiency syndrome; CI, confidence interval; HIV, human immunodeficiency virus; RR, relative risk. 




















0.62 (0.01, 1.23) 
0.62 (0.01, 1.23) 
3.91 (2.48, 5.33) 
3.91 (2.48, 5.33) 
3.41 (−0.45, 7.27) 
3.41 (−0.45, 7.27) 
0.39 (0.10, 0.68) 
0.39 (0.10, 0.68) 
0.48 (0.26, 0.70) 
0.48 (0.26, 0.70) 
2.97 (2.36, 3.58) 
2.97 (2.36, 3.58) 
1.73 (1.43, 2.02) 
1.73 (1.43, 2.02) 
9.12 (8.13, 10.10) 
9.12 (8.13, 10.10) 
1.74 (0.83, 2.65) 
1.74 (0.83, 2.65) 
1.94 (1.69, 2.20) 
1.94 (1.69, 2.20) 
2.73 (2.28, 3.17) 
2.73 (2.28, 3.17) 
3.37 (1.61, 5.14) 
3.37 (1.61, 5.14) 
1.71 (0.74, 2.68) 
1.71 (0.74, 2.68) 
1.24 (0.25, 2.23) 
1.24 (0.25, 2.23) 
2.83 (2.25, 3.42) 
2.83 (2.25, 3.42) 
8.64 (3.94, 13.34) 
8.64 (3.94, 13.34) 
% 
Weight 
7.11 
7.11 
5.84 
5.84 
2.44 
2.44 
7.38 
7.38 
7.42 
7.42 
7.10 
7.10 
7.38 
7.38 
6.59 
6.59 
6.70 
6.70 
7.40 
7.40 
7.27 
7.27 
5.22 
5.22 
6.61 
6.61 
6.57 
6.57 
7.13 
7.13 
1.84 
1.84 

2.55 (1.81, 3.28) 
2.55 (1.81, 3.28) 
100.00 
100.00 

















% 
Weight 
1.96 (1.28, 3.01) 
1.96 (1.28, 3.01) 
7.65 
7.65 
1.77 (0.78, 4.02) 
1.77 (0.78, 4.02) 
4.68 
4.68 
2.80 (2.12, 3.70) 
2.80 (2.12, 3.70) 
8.85 
8.85 
1.15 (0.94, 1.40) 
1.15 (0.94, 1.40) 
9.38 
9.38 
3.77 (2.11, 6.74) 
3.77 (2.11, 6.74) 
6.38 
6.38 
1.31 (1.18, 1.46) 
1.31 (1.18, 1.46) 
9.81 
9.81 
1.98 (1.67, 2.36) 
1.98 (1.67, 2.36) 
9.51 
9.51 
0.57 (0.42, 0.79) 
0.57 (0.42, 0.79) 
8.55 
8.55 
1.52 (0.87, 2.65) 
1.52 (0.87, 2.65) 
6.58 
6.58 
1.83 (1.21, 2.77) 
1.83 (1.21, 2.77) 
7.75 
7.75 
2.66 (1.66, 4.25) 
2.66 (1.66, 4.25) 
7.30 
7.30 
0.62 (0.30, 1.29) 
0.62 (0.30, 1.29) 
5.26 
5.26 
1.96 (1.38, 2.78) 
1.96 (1.38, 2.78) 
8.31 
8.31 

1.63 (1.28, 2.08) 
1.63 (1.28, 2.08) 
100.00 
100.00 

 
 
 
 

Systematic reviews 
Mortality among people who inject drugs 

Image produced using Stata (StataCorp. LP, College Station, TX, United States of America). 
CI, confidence interval; HIV, human immunodeficiency virus; RR, relative risk. 






Image produced using Stata (StataCorp. LP, College Station, TX, United States of America). 
AIDS, acquired immunodeficiency syndrome; CI, confidence interval; HIV, human immunodeficiency virus; RR, relative risk. 


1 
















% 
Weight 

2.02 (1.18, 3.45) 

13.24 

2.41 (0.58, 10.05) 

5.74 

3.51 (2.33, 5.28) 

14.52 

1.04 (0.70, 1.56) 

14.57 

3.90 (1.36, 11.18) 

8.22 

0.77 (0.43, 1.38) 

12.75 

2.18 (0.92, 5.16) 

9.88 

3.63 (1.32, 9.94) 

8.58 

2.09 (1.14, 3.83) 

12.50 

1.99 (1.31, 3.04) 

100.00 















% 
Weight 
0.20 (0.07, 0.56) 
0.20 (0.07, 0.56) 
6.84 
6.84 
4.83 (2.02, 11.57) 
4.83 (2.02, 11.57) 
7.34 
7.34 
1.50 (0.26, 8.76) 
1.50 (0.26, 8.76) 
4.60 
4.60 
0.17 (0.08, 0.38) 
0.17 (0.08, 0.38) 
7.57 
7.57 
0.18 (0.10, 0.32) 
0.18 (0.10, 0.32) 
8.25 
8.25 
3.13 (2.06, 4.73) 
3.13 (2.06, 4.73) 
8.62 
8.62 
5.08 (3.34, 7.72) 
5.08 (3.34, 7.72) 
8.61 
8.61 
2.00 (0.81, 4.93) 
2.00 (0.81, 4.93) 
7.24 
7.24 
1.81 (1.13, 2.88) 
1.81 (1.13, 2.88) 
8.51 
8.51 
1.75 (0.74, 4.13) 
1.75 (0.74, 4.13) 
7.39 
7.39 
1.20 (0.52, 2.76) 
1.20 (0.52, 2.76) 
7.47 
7.47 
1.70 (1.42, 2.04) 
1.70 (1.42, 2.04) 
8.99 
8.99 
3.56 (2.29, 5.53) 
3.56 (2.29, 5.53) 
8.56 
8.56 

1.35 (0.79, 2.31) 
1.35 (0.79, 2.31) 
100.00 
100.00 

 
 
 
 
Systematic reviews 
Mortality among people who inject drugs 


Image produced using Stata (StataCorp. LP, College Station, TX, United States of America). 
CI, confidence interval; HIV, human immunodeficiency virus; RR, relative risk. 




Image produced using Stata (StataCorp. LP, College Station, TX, United States of America). 
CI, confidence interval; HIV, human immunodeficiency virus; RR, relative risk. 




in countries where drug injecting is 
taking place but little research has been 
conducted about it. 
In this review we found no signifi- 
cant differences in the risk of death by 
type of primary drug injected. This con- 
trasts with the findings of other reviews 
of people dependent on different drug 
types, which, despite their own limita- 
tions, have suggested differences in 
mortality among opioid-, amphetamine- 
and cocaine-dependent persons.3–5 An 
explanation for this discrepancy might 
lie in the extent of drug injection among 
the groups examined, whether people 
used multiple drugs (polydrug use be- 
ing the norm), or the possibility, seldom 
examined, that some people in the co- 
horts switched from one primary drug 
to another during the follow-up period. 
All of these factors would have reduced 
our capacity to detect any differences in 
mortality among people injecting differ- 
ent types of drugs. 
The ability to detect differences in 
mortality in cohort studies according to 
HIV status is subject to limitations. HIV 
status was typically measured at baseline 
only, and some subjects who contracted 
HIV infection during follow-up would 
remain assigned to the HIV− group for 
the entire follow-up period. Nonethe- 
less, this would only serve to underesti- 
mate the relative differences in mortality 
between HIV+ and HIV− people who 
inject drugs. The markedly higher all- 




% 
Weight 

2.14 (0.77, 5.93) 
2.14 (0.77, 5.93) 
27.67 
27.67 


1.46 (0.62, 3.44) 
1.46 (0.62, 3.44) 
39.31 
39.31 
2.02 (0.79, 5.15) 
2.02 (0.79, 5.15) 
33.02 
33.02 

1.81 (1.06, 3.09) 
1.81 (1.06, 3.09) 
100.00 
100.00 







1.45 (0.65, 3.23) 

3.99 




1.01 (0.81, 1.26) 

52.62 

1.22 (0.89, 1.68) 

25.88 

1.30 (0.89, 1.91) 

17.50 


1.13 (0.96, 1.32) 

100.00 

 
 
 
 

Systematic reviews 
Mortality among people who inject drugs 























Systematic reviews 
Mortality among people who inject drugs 


Image produced using Stata (StataCorp. LP, College Station, TX, United States of America). 
CI, confidence interval; RR, relative risk. 




Table 3. Univariate associations between study-level variables and all-cause crude 
mortality rates (CMRs) and standardized mortality ratios (SMRs) 
Geographic region 
Country income 
Percentage of cohort who inject drugs 
Percentage of males 
Percentage of cohort HIV+ at baseline 
Presence of people using opioids 
(alone or with other drugs) in cohort 
Year in which follow-up ceased 
−1.05 
3.03 
1.49 
3.40 
2.42 
−0.07 
0.298 
0.004 
0.141 
0.001 
0.022 
0.945 
53 
67 
60 
57 
30 
67 
0.74 
0.65 
2.04 
0.29 
1.00 
−1.28 
0.466 
0.519 
0.052 
0.771 
0.349 
0.209 
23 
33 
26 
31 
9 
33 
cause mortality that we observed among 
HIV+ people who inject drugs is there- 
fore probably a conservative estimate of 
the elevation in mortality in that group. 
Misattribution of cause of death as either 
AIDS- or non-AIDS-related could have 
occurred as well. 
Treatment for HIV infection has 
improved greatly and has become more 
widely available. In some cohorts, mor- 
tality was examined for the periods be- 
fore and after highly active antiretroviral 
therapy (HAART) was introduced. The 
findings suggest that mortality among 
HIV+ people who inject drugs decreased 
after the widespread introduction of 
HAART.55 Unfortunately, we were un- 
able to examine the impact of treatment 
for HIV infection across studies because 
mortality was rarely reported separately 
for the periods before and after the in- 
troduction of HAART.77 However, the 
observed association between cohorts 
with more recent follow-up periods and 
lower SMRs might have to do with the 
greater availability in recent years of ef- 
fective interventions for the prevention 
and treatment of HIV infection. 
Reporting quality was poor. Few 
studies met criteria in consensus state- 
ments for the reporting of observational 
studies.7 Mortality estimates were re- 
ported in various forms, including odds 
ratios, relative risks, hazard ratios and 
CMRs. Most studies did not report 
SMRs and many failed to report standard 
parameters such as PY, or were seldom 
easy to calculate, particularly for disag- 
gregated mortality estimates. As a result, 
only a subset of studies could be included 
in many of the analyses. 
Causes of death were not uniformly 
or consistently coded. Deaths from 
drug overdose might have been missed 
in countries with limited capacity to 
conduct toxicological tests or where 
recording a death as being from a drug 
overdose is surrounded by stigma. As 
a result, we may have underestimated 
CMRs and SMRs for death from drug 
overdose. Misattribution of deaths by 
HIV status may have occurred, since 
most cohorts were assessed for HIV 
status at the beginning of the study only 
and people infected during follow-up 
could have been missed. Again, this may 
have resulted in conservative estimates 
of mortality among HIV+ people who 
inject drugs and in lower effect sizes. In 
future research, assessing individuals’ 
HIV status at several time points during 
the follow-up period would allow a more 
accurate measurement of mortality in 
relation to HIV status. 










% 
Weight 
1.96 (1.50, 2.56) 
1.96 (1.50, 2.56) 
18.67 
18.67 
1.90 (1.40, 2.59) 
1.90 (1.40, 2.59) 
18.32 
18.32 
10.86 (7.25, 16.26) 
10.86 (7.25, 16.26) 
17.30 
17.30 
1.92 (1.79, 2.05) 
1.92 (1.79, 2.05) 
19.85 
19.85 
1.19 (0.58, 2.45) 
1.19 (0.58, 2.45) 
13.37 
13.37 
2.55 (1.15, 5.66) 
2.55 (1.15, 5.66) 
12.49 
12.49 

2.52 (1.59, 4.00) 
2.52 (1.59, 4.00) 
100.00 
100.00 
















 
 

Systematic reviews 
Mortality among people who inject drugs 

Image produced using Stata (StataCorp. LP, College Station, TX, United States of America). 
CI, confidence interval; CMR, crude mortality rate. 









% 
Weight 
2.01 (1.79, 2.16) 
2.01 (1.79, 2.16) 
2.15 (2.05, 2.25) 
2.15 (2.05, 2.25) 
5.42 (3.45, 7.40) 
5.42 (3.45, 7.40) 
2.04 (1.26, 2.83) 
2.04 (1.26, 2.83) 
2.26 (2.08, 2.43) 
2.26 (2.08, 2.43) 
1.95 (1.70, 2.23) 
1.95 (1.70, 2.23) 
2.45 (2.06, 2.84) 
2.45 (2.06, 2.84) 
1.00 (0.86, 1.15) 
1.00 (0.86, 1.15) 
0.74 (0.59, 0.88) 
0.74 (0.59, 0.88) 
0.89 (0.86, 0.92) 
0.89 (0.86, 0.92) 
1.27 (0.40, 2.29) 
1.27 (0.40, 2.29) 
3.33 (2.98, 3.68) 
3.33 (2.98, 3.68) 
1.09 (0.93, 1.25) 
1.09 (0.93, 1.25) 
2.77 (2.22, 3.42) 
2.77 (2.22, 3.42) 
3.68 (3.11, 4.25) 
3.68 (3.11, 4.25) 
0.91 (0.62, 1.20) 
0.91 (0.62, 1.20) 
7.14 (5.22, 9.06) 
7.14 (5.22, 9.06) 
2.08 (1.52, 2.64) 
2.08 (1.52, 2.64) 
3.85 (2.94, 4.76) 
3.85 (2.94, 4.76) 
1.99 (1.72, 2.25) 
1.99 (1.72, 2.25) 
7.76 (5.54, 10.58) 
7.76 (5.54, 10.58) 
2.52 (2.28, 2.77) 
2.52 (2.28, 2.77) 
1.57 (1.41, 1.75) 
1.57 (1.41, 1.75) 
4.67 (4.42, 4.92) 
4.67 (4.42, 4.92) 
4.22 (2.80, 5.64) 
4.22 (2.80, 5.64) 
1.92 (0.95, 3.44) 
1.92 (0.95, 3.44) 
1.61 (1.13, 2.23) 
1.61 (1.13, 2.23) 
2.02 (1.92, 2.12) 
2.02 (1.92, 2.12) 
0.84 (0.75, 0.93) 
0.84 (0.75, 0.93) 
2.18 (2.00, 2.36) 
2.18 (2.00, 2.36) 
2.04 (1.80, 2.30) 
2.04 (1.80, 2.30) 
1.05 (0.69, 1.41) 
1.05 (0.69, 1.41) 
2.91 (2.48, 3.33) 
2.91 (2.48, 3.33) 
1.37 (0.80, 1.94) 
1.37 (0.80, 1.94) 
2.43 (2.16, 2.69) 
2.43 (2.16, 2.69) 
3.74 (3.38, 4.14) 
3.74 (3.38, 4.14) 
1.30 (1.12, 1.48) 
1.30 (1.12, 1.48) 
1.59 (1.22, 1.96) 
1.59 (1.22, 1.96) 
1.83 (1.28, 2.38) 
1.83 (1.28, 2.38) 
0.50 (0.36, 0.65) 
0.50 (0.36, 0.65) 
3.40 (2.36, 4.44) 
3.40 (2.36, 4.44) 
2.33 (1.60, 3.27) 
2.33 (1.60, 3.27) 
3.49 (2.45, 4.53) 
3.49 (2.45, 4.53) 
2.12 (1.93, 2.31) 
2.12 (1.93, 2.31) 
0.83 (0.56, 1.21) 
0.83 (0.56, 1.21) 
0.50 (0.29, 0.72) 
0.50 (0.29, 0.72) 
3.23 (2.56, 4.07) 
3.23 (2.56, 4.07) 
4.50 (4.24, 4.76) 
4.50 (4.24, 4.76) 
0.71 (0.54, 0.88) 
0.71 (0.54, 0.88) 
0.48 (0.15, 0.81) 
0.48 (0.15, 0.81) 
2.30 (1.96, 2.63) 
2.30 (1.96, 2.63) 
2.17 (1.92, 2.42) 
2.17 (1.92, 2.42) 
6.32 (4.68, 7.96) 
6.32 (4.68, 7.96) 
3.52 (2.46, 4.59) 
3.52 (2.46, 4.59) 
2.77 (1.45, 4.09) 
2.77 (1.45, 4.09) 
0.57 (0.47, 0.68) 
0.57 (0.47, 0.68) 
1.18 (0.91, 1.46) 
1.18 (0.91, 1.46) 
1.60 (1.43, 1.77) 
1.60 (1.43, 1.77) 
4.08 (1.25, 6.91) 
4.08 (1.25, 6.91) 
6.89 (5.79, 7.98) 
6.89 (5.79, 7.98) 
2.28 (1.81, 2.83) 
2.28 (1.81, 2.83) 
3.85 (2.42, 5.83) 
3.85 (2.42, 5.83) 
6.30 (4.60, 8.50) 
6.30 (4.60, 8.50) 
4.83 (0.00, 14.30) 
4.83 (0.00, 14.30) 
4.25 (3.35, 5.16) 
4.25 (3.35, 5.16) 
7.73 (4.87, 10.60) 
7.73 (4.87, 10.60) 
3.53 (2.81, 4.24) 
3.53 (2.81, 4.24) 
1.83 
1.83 
1.84 
1.84 
0.77 
0.77 
1.51 
1.51 
1.83 
1.83 
1.80 
1.80 
1.75 
1.75 
1.83 
1.83 
1.83 
1.83 
1.85 
1.85 
1.40 
1.40 
1.77 
1.77 
1.83 
1.83 
1.64 
1.64 
1.66 
1.66 
1.79 
1.79 
0.80 
0.80 
1.66 
1.66 
1.43 
1.43 
1.80 
1.80 
0.57 
0.57 
1.81 
1.81 
1.83 
1.83 
1.81 
1.81 
1.08 
1.08 
1.19 
1.19 
1.67 
1.67 
1.84 
1.84 
1.84 
1.84 
1.83 
1.83 
1.81 
1.81 
1.77 
1.77 
1.74 
1.74 
1.65 
1.65 
1.80 
1.80 
1.76 
1.76 
1.83 
1.83 
1.76 
1.76 
1.67 
1.67 
1.83 
1.83 
1.33 
1.33 
1.48 
1.48 
1.33 
1.33 
1.82 
1.82 
1.78 
1.78 
1.82 
1.82 
1.54 
1.54 
1.80 
1.80 
1.83 
1.83 
1.78 
1.78 
1.78 
1.78 
83.99 
83.99 
0.94 
0.94 
1.31 
1.31 
1.14 
1.14 
1.84 
1.84 
1.80 
1.80 
1.83 
1.83 
0.48 
0.48 
1.29 
1.29 
1.69 
1.69 
0.91 
0.91 
0.78 
0.78 
0.10 
0.10 
1.43 
1.43 
0.47 
0.47 
16.01 
16.01 
2.35 (2.12, 2.58) 
2.35 (2.12, 2.58) 
100.00 
100.00 
high income 
Antolini 2006 (Italy) 
Bargagli 2001 (Italy) 
Bauer 2008 (Austria) 
Brancato 1995 (Italy) 
Ciccolallo 2000 (Italy) 
Clausen 2008 (Norway) 
Copeland 2004 (UK) 
Cornish 2010 (UK) 
Davoli 2007 (Italy) 
Degenhardt 2009 (Australia) 
Digusto 2004 (Australia) 
EMCDDA 2011 (Sweden) 
EMCDDA 2011 (Croatia) 
Eskild 1993 (Norway) 
Esteban 2003 (Spain) 
Evans 2012 (USA) 
Fingerhood 2006 (USA) 
Frischer 1997 (UK) 
Fugelstad 1995 (Sweden) 
Fugelstad 1997 (Sweden) 
Fugelstad 1998 (Sweden) 
Galli 1994 (Italy) 
Goedert 1995 (Italy) 
Goedert 2001 (USA) 
Golz 2001 (Germany) 
Haarr 2007 (Norway) 
Hickman 2003 (UK) 
Jarrin 2007 (Spain) 
Lejckova 2007 (Czech Republic) 
Lumbreras 2006 (Spain) 
Manfredi 2006 (Italy) 
McAnulty 1995 (USA) 
Mezzelani 1998 (Italy) 
Miller 2007 (Canada) 
Moroni 1991 (Italy) 
Muga 2007 (Spain) 
Nyhlen 2011 (Sweden) 
O’Driscoll 2001 (USA) 
Oppenheimer 1994 (UK) 
Reece 2010 (Australia) 
Sanchez−Carbonell 2000 (Spain) 
Seaman 1998 (UK) 
Sorensen 2005 (Denmark) 
Stenbacka 2007 (Sweden) 
Stoove 2008 (Australia) 
Tait 2008 (Australia) 
VanHaastrecht 1996 (Netherlands) 
Vlahov 2005 (USA) 
Vlahov 2008 (USA) 
Zabransky 2011 (Czech Republic) 
Zaccarelli 1994 (Italy) 
Subtotal (I−squared = 98.8%, p = 0.000) 
. 
low and middle income 
Azim 2008 (Bangladesh) 
Azim 2009 (Bangladesh) 
Cardoso 2006 (Brazil) 
EMCDDA 2011 (Romania) 
EMCDDA 2011 (Bulgaria) 
EMCDDA 2011 (Latvia) 
Jafan 2010 (Islamic Republic of Iran) 
Liu 2011 (China) 
Moskalewicz 1996 (Poland) 
Quan 2007 (Thailand) 
Quan 2010 (Viet Nam) 
Rahimi-Movahgar 2009 (Islamic Republic of Iran) 
Solomon 2009 (India) 
Zhang 2005 (China) 
Subtotal (I−squared = 97.0%, p = 0.000) 



 
 
Systematic reviews 
Mortality among people who inject drugs 
Limitations of the review and 
meta-analysis 
Our review has limitations. The lag 
time between the date when the studies 
were conducted and when they were 
published in peer-reviewed journals was 
generally long. In light of this we used 
several methods to search for published 
and unpublished studies. We reviewed 
primarily English-language papers, 
although we also reviewed the abstracts 
of non-English-language peer-reviewed 
articles when they were available in 
English. When studies seemed relevant, 
we had them translated; we engaged ex- 
perts from a range of different countries 
and language groups to review these 
reference lists. Meta-analytical methods 
were originally developed to aggregate 
the findings of randomized controlled 
trials,85 which have the advantage of 
allowing for control or adjustment of 
pre-conditions and sample-related fac- 
tors that could influence the outcomes 
of interest. Controlling for such factors 
is not possible in observational studies, 
like the ones included in our review. 

People who inject drugs have a much 
higher risk of death than those who do 
not. Major causes of death in this group 
are often poorly specified, but death 
from drug overdose is common, as is 

AIDS-related mortality in settings with a 
high prevalence of HIV infection. HIV+ 
people who inject drugs have higher 
mortality not just from HIV-related 
causes but also from drug overdose. 
Mortality varies by participant- and 
study-level characteristics, which sug- 
gests that multiple factors contribute 
to the higher risk of death observed in 
people who inject drugs. Many of these 
factors are probably modifiable, since 
certain predominant causes of death ac- 
count for most of the mortality observed 
in this group. ■ 

 14.68 ةدحولما تايفولا ةبسن تناكو ؛ةعوممج ينثلاثو ينتنثلا 
 ةنراقم ترهظأو .)16.35 لىإ 13.01 :% 95 ةقثلا لصاف( 
 تايفولا تلادعم بسن باسحو ةيلولأا تايفولا تلادعم 
 ةطسوتلماو ةضفخنلما نادلبلا في تايفولا لدعم عافترا ةيلولأا 
 سويرفل ينيبايجلإا صاخشلأاو روكذلاو تاعومجلما ينب لخدلا 
 قيرط نع تاردخلما اوطاعت نيذلا )HIV( يشربلا يعانلما زوعلا 
 .جلاعلا فقو تاترف للاخ كلذك ًاعفترم لدعلما ناكو .نقلحا 
 بستكلما يعانلما زوعلا ةمزلاتمو تاردخلما ةعرج طرف ناكو 
.تاعومجلما ينب ةافولل ينيسيئرلا ينببسلا )زديلأا( 
 نيذلا صاخشلأا ضرعتي ،ناكسلا ةماعب ةنراقم جاتنتسلاا 
 مغرلا لىع ،عفترم ةافو رطلخ نقلحا قيرط نع تاردخلما نوطاعتي 
 نأ بيجو .ةفلتخلما تائيبلا ينب تايفولا تلادعم توافت نم 
 ًادوهج ةئفلا هذه في ةحصلا لئاصح ينسحتل لماش جنه يأ نمضتي 
 ةفاضلإاب يشربلا يعانلما زوعلا سويرفب ةباصلإا ىودع ضفلخ 
 .تاردخلما ةعرج طرف مايسلاو ،ةافولا بابسأ نم اهيرغ لىإ 
صخلم 
يفصو ليلتحو يجهنم ضارعتسا :نقلحا قيرط نع تاردخلما نوطاعتي نيذلا صاخشلأا ينب تايفولا لدعم 
 ينب تايفولا لدعمب ةينعلما ةيبارتلأا تاساردلا ضارعتسا ضرغلا 
 وحن لىع نقلحا قيرط نع تاردخلما نوطاعتي نيذلا صاخشلأا 
 ،ةئفلا هذه في ةافولا بابسأو تايفولا تلادعم ةساردو ،يجهنم 
 عافتراب ةطبترلما ةساردلاو ينكراشلما ىوتسم تايرغتم ديدتحو 
.ةافولا رطخ 
 دعاوق في ثحبلل ةصصمخ ثحب تارابع مادختسا مت ةقيرطلا 
 ديدتح متو .PsycINFOو Medlineو EMBASE تانايب 
 يرغ تاباتكلا تانايب دعاوق للاخ نم ةيمسرلا يرغ تاباتكلا 
 لوصحلل ءابرلخا ةراشتسا متو .تنترنلإا ةكبش لىع ةيمسرلا 
 ةيفصولا تلايلحتلا ءارجإ متو .ةيفاضإ تانايبو تاسارد لىع 
 ةعمجلما ةيلولأا تايفولا تلادعم مييقتل ةيئاوشعلا تايرثأتلل 
.)SMRs( ةدحولما تايفولا بسنو )CMRs( 
 نيذلا صاخشلأا نم ةعوممج ينتسو عبس ديدتح مت جئاتنلا 
 نادلبلا نم اهنم ةشرع عبرأ ،نقلحا قيرط نع تاردخلما نوطاعتي 
 عمجلما ليولأا تايفولا لدعم ناكو .لخدلا ةطسوتلماو ةضفخنلما 
 لصاف ،% 95 ةقثلا لصاف( ةنس-صخش 100 لكل ةافو 2.35 
 ةدحولما تايفولا بسن نع غلابلإا متو .)2.58 لىإ 2.12 :ةقثلا 

药物注射人群的死亡率：系统回顾和荟萃分析 
目的 系统回顾药物注射人群死亡率的队列研究，检查该群 
体的死亡率和死亡原因，并确定与较高死亡风险相关的参 
与水平和研究水平变量。 
方法 使用定制的搜索字符串搜索EMBASE、Medline和 
PsycINFO。通过网上灰色文献数据库识别灰色文献。咨询 
专家以获取更多的研究和数据。执行随机效果荟萃分析来 
估计汇集的粗死亡率（CMR）和标准化死亡率（SMR）。 
结果 确定67 个药物注射人群队列，其中14 个来自中低 
收入国家。汇集的CMR为每100 人年2.35 例死亡（95% 
置信区间，CI：2.12-2.58）。报告32 个队列的SMR；汇 
集的SMR为14.68（95% CI：13.01-16.35）。CMR的比 
较和CMR比率的计算表明，中低收入国家的队列、男性 
以及艾滋病毒（HIV）呈阳性的药物注射人群中的死亡率 
较高。治疗结束期间死亡率也较高。药物过量和艾滋病 
（AIDS）是各个队列的主要死亡原因。 
结论 尽管不同环境中的死亡率各异，与普通人群相比，药 
物注射人群的死亡风险更高。任何改善该群体的健康疗效 
的综合方案都必须包括减少艾滋病毒感染以及其他死亡致 
因（尤其是药物过量）的努力。 




Systematic reviews 
Mortality among people who inject drugs 
Mortalité chez les personnes qui s’injectent des drogues : revue systématique et méta-analyse 
Objectif Examiner systématiquement les études de cohortes de la 
mortalité chez les toxicomanes par injection, étudier les taux de mortalité 
et les causes de décès dans ce groupe, et identifier les variables, au niveau 
des participants et des études, associées à un risque accru de décès. 
Méthodes Des critères de recherche spécifiquement adaptés ont été 
utilisés pour les recherches réalisées sur EMBASE, Medline et PsycINFO. 
La littérature grise a été identifiée par le biais de bases de données de 
littérature grise disponibles en ligne. Des experts ont été consultés pour 
obtenir des données et des études supplémentaires. Des méta-analyses 
des effets aléatoires ont été réalisées afin d’estimer les taux bruts de 
mortalité (TBM) groupés et les taux de mortalité standardisés (TMS). 
Résultats Soixante-sept cohortes de personnes qui s’injectent des 
drogues ont été identifiées, dont 14 appartenant à des pays à revenu 
faible et intermédiaire. Le TBM groupé était de 2,35 décès pour 
100 personnes-années (intervalle de confiance de 95%, IC: 2,12 – 2,58). 
décès parmi ces cohortes. 
Les TMS étaient indiqués pour 32 cohortes, avec un TMS groupé de 14,68 
(IC de 95%: 13,01 – 16,35). La comparaison des TBM et le calcul des taux 
de TMS ont révélé une mortalité plus élevée parmi les cohortes des pays 
à revenu faible et intermédiaire, les sujets masculins et les toxicomanes 
par injection séropositifs. Elle était également plus élevée pendant 
les périodes d’interruption thérapeutique. L’overdose et le syndrome 
d’immunodéficience acquise (SIDA) étaient les causes principales des 
Conclusion Si l’on compare avec la population globale, les personnes 
qui s’injectent des drogues ont un risque élevé de décès, bien que les 
taux de mortalité varient selon les contextes. Toute approche exhaustive 
visant à améliorer les résultats de ce groupe en matière de santé doit 
comprendre des efforts en vue de diminuer l’infection par le VIH, ainsi 
que d’autres causes de décès, notamment l’overdose. 

Смертность среди лиц, вводящих наркотики внутривенно: систематический обзор и мета-анализ 
Цель Провести систематический обзор когортных исследований 
смертности среди лиц, вводящих наркотики внутривенно, 
изучить уровни смертности и причины смерти в данной группе и 
определить переменные на уровне участников и исследований, 
связанные с высоким риском смерти. 
Методы Поиск исследований осуществлялся по базам данных 
EMBASE, Medline и PsycINFO по специализированным критериям 
поиска. Поиск литературы для служебного пользования 
осуществлялся по онлайновым базам данных литературы для 
служебного пользования. С целью получения дополнительных 
данных и исследований проводились консультации с экспертами. 
Для определения суммарных общих показателей смертности 
(ОПС) и стандартизированных коэффициентов смертности (СКС) 
выполнялся мета-анализ случайных эффектов. 
Результаты Были выявлены шестьдесят семь когорт лиц, 
вводящих наркотики внутривенно, 14 из которых относятся к 
странам с низким и средним уровнями доходов. Суммарный ОПС 
составлял 2,35 смертей на 100 человеко-лет (95% доверительный 
являлись основными причинами смерти в когортах. 
интервал, ДИ: 2,12–2,58). СКС фиксировался для 32 когорт; 
суммарный СКС составлял 14,68 (95% ДИ: 13,01-16,35). Сравнение 
ОПС и расчет коэффициентов ОПС выявил высокий уровень 
смертности в когортах, относящихся к странам с низким и 
средним уровнями доходов, среди мужчин и лиц, вводивших 
наркотики внутривенно, которые имели положительные 
результаты на вирус иммунодефицита человека (ВИЧ). Высокий 
уровень также отмечен вне периодов лечения. Передозировка 
наркотиков и синдром приобретенного иммунодефицита (СПИД) 
Вывод По сравнению с населением в целом, лица, вводящие 
наркотики внутривенно, подвержены повышенному риску 
смерти несмотря на то, что уровни смертности варьируются 
в зависимости от условий. Любой комплексный подход к 
улучшению результатов мероприятий по охране здоровья в 
данной группе должен включать в себя меры по сокращению 
уровня ВИЧ-инфекции, а также других причин смерти, в 
особенности, передозировки наркотиков. 

La mortalidad entre consumidores de drogas inyectables: una revisión sistemática y meta-análisis 
Objetivo Revisar de forma sistemática los estudios de cohortes sobre la 
mortalidad entre los consumidores de drogas inyectables, examinar las 
tasas de mortalidad y las causas de muerte en este grupo e identificar 
las variables relacionadas con el estudio y los participantes asociadas a 
un mayor riesgo de muerte. 
Métodos Se emplearon cadenas de búsqueda adaptadas para registrar 
EMBASE, Medline y PsycINFO. La literatura gris se identificó por medio de 
bases de datos de literatura gris en línea. Se consultaron expertos a fin 
de obtener datos y estudios adicionales y se llevaron a cabo metaanálisis 
de efectos aleatorios para calcular las tasas brutas combinadas de 
mortalidad y las tasas de mortalidad estandarizadas. 
Resultados Se identificaron diecisiete cohortes de consumidores 
de drogas inyectables, 14 de las cuales en países con ingresos 
bajos y medios. La tasa bruta combinada de mortalidad fue de 2,35 
fallecimientos por cada 100 años-persona (intervalo de confianza del 
95%, IC: 2,12-2,58). Se declararon las tasas de mortalidad estandarizadas 
muerte, en especial, la sobredosis. 
para 32 cohortes; la tasa bruta combinada de mortalidad fue de 14,68 
(IC 95%: 13,01-16,35). La comparación de las tasas brutas combinadas 
de mortalidad y el cálculo de las proporciones de la mortalidad 
bruta combinada revelaron que la mortalidad fue superior en las 
cohortes de países con ingresos bajos y medios, en varones y entre 
consumidores de drogas inyectables que dieron positivo para el virus 
de la inmunodeficiencia humana (VIH), así como durante los periodos 
sin tratamiento. Las sobredosis y el síndrome de la inmunodeficiencia 
adquirida (SIDA) fueron las causas principales de muerte en las cohortes. 
Conclusión En comparación con la población general, los consumidores 
de drogas inyectables presentan un riesgo elevado de muerte, si bien 
las tasas de mortalidad varían en los distintos lugares. Cualquier enfoque 
completo para mejorar los resultados sanitarios en este grupo deberá 
esforzarse por reducir la infección por VIH, así como las otras causas de 


Systematic reviews 
Mortality among people who inject drugs 

References 
1. Darke S, Degenhardt L, Mattick RP, editors. Mortality amongst illicit drug users. 

2. Degenhardt L, Hall W, Warner-Smith M. Using cohort studies to estimate 
mortality among injecting drug users that is not attributable to AIDS. Sex 
Transm Infect 2006;82:iii56–63. doi:10.1136/sti.2005.019273 PMID:16735295 
3. Degenhardt L, Singleton J, Calabria B, McLaren J, Kerr T, Mehta S et al. Mortality 

among cocaine users: a systematic review of cohort studies. Drug Alcohol Depend 
2011;113:88–95. doi:10.1016/j.drugalcdep.2010.07.026 PMID:20828942 
Singleton J, Degenhardt L, Hall W, Zabransky T. Mortality among amphetamine 
users: a systematic review of cohort studies. Drug Alcohol Depend 2009;105:1–8. 
doi:10.1016/j.drugalcdep.2009.05.028 PMID:19631479 

5. Degenhardt L, McLaren J, Ali H, Briegleb C; Global Burden of Disease Mental 
Disorders and Illicit Drug Use Expert Group. Methods used in a systematic 
review of mortality among dependent users of heroin and other opioids. Sydney: 
National Drug and Alcohol Research Centre, University of New South Wales; 
2008 (Illicit drugs discussion paper No. 9). 
Calabria B, Phillips B, Singleton J, Mathers BM, Congreve E, Degenhardt L, et al. 
Searching the grey literature to access information on drug and alcohol research: A 
resource to identify drug related databases and websites. Sydney: National Drug 
and Alcohol Research Centre, University of New South Wales; 2008. 
Vandenbroucke JP, von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock 
SJ et al. STROBE Initiative. Strengthening the reporting of observational 
studies in epidemiology (STROBE): explanation and elaboration. Epidemiology 
2007;18:805–35. doi:10.1097/EDE.0b013e3181577511 PMID:18049195 


during and after opiate substitution treatment in primary care: prospective 
observational study in UK General Practice Research Database. BMJ 
2010;341:c5475. doi:10.1136/bmj.c5475 PMID:20978062 
24. Copeland L, Budd J, Robertson JR, Elton RA. Changing patterns in causes 
of death in a cohort of injecting drug users, 1980–2001. Arch Intern Med 
2004;164:1214–20. doi:10.1001/archinte.164.11.1214 PMID:15197047 
25. Davoli M, Bargagli AM, Perucci CA, Schifano P, Belleudi V, Hickman M et al. 
VEdeTTE Study Group. Risk of fatal overdose during and after specialist 
drug treatment: the VEdeTTE study, a national multi-site prospective cohort 
study. Addiction 2007;102:1954–9. doi:10.1111/j.1360-0443.2007.02025.x 
PMID:18031430 
26. Degenhardt L, Randall D, Hall W, Law M, Butler T, Burns L. Mortality among 
clients of a state-wide opioid pharmacotherapy program over 20 years: risk 
factors and lives saved. Drug Alcohol Depend 2009;105:9–15. doi:10.1016/j. 
drugalcdep.2009.05.021 PMID:19608355 
27. DiGiusto E, Shakeshaft A, Ritter A, O’Brien S, Mattick RP; NEPOD Research 
Group. Serious adverse events in the Australian National Evaluation of 
Pharmacotherapies for Opioid Dependence (NEPOD). Addiction 2004;99:450– 
60. doi:10.1111/j.1360-0443.2004.00654.x PMID:15049745 

mortality rates and causes of death between HIV positive and HIV negative 
intravenous drug users. Int J Epidemiol 1993;22:315–20. doi:10.1093/ 
ije/22.2.315 PMID:8505190 
8. Wilcox HC, Conner KR, Caine ED. Association of alcohol and drug use disorders 
and completed suicide: an empirical review of cohort studies. Drug Alcohol 
Depend 2004;76(Suppl):S11–9. doi:10.1016/j.drugalcdep.2004.08.003 
PMID:15555812 
29. Esteban J, Gimeno C, Barril J, Aragonés A, Climent JM, de la Cruz Pellín M. 
Survival study of opioid addicts in relation to its adherence to methadone 
maintenance treatment. Drug Alcohol Depend 2003;70:193–200. doi:10.1016/ 
S0376-8716(03)00002-4 PMID:12732413 
9. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 
1986;7:177–88. doi:10.1016/0197-2456(86)90046-2 PMID:3802833 
10. Sharp S, Sterne J. Meta-analysis. Stata Tech Bull 1997;38:9–14. 
11. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency 
in meta-analyses. BMJ 2003;327:557–60. doi:10.1136/bmj.327.7414.557 
PMID:12958120 
12. Sharp S, Sterne J. Meta-analysis regression. Stata Tech Bull 1998;42:16–24. 
13. Thompson SG, Sharp SJ. Explaining heterogeneity in meta-analysis: a 
comparison of methods. Stat Med 1999;18:2693–708. doi:10.1002/(SICI)1097- 
0258(19991030)18:20<2693::AID-SIM235>3.0.CO;2-V PMID:10521860 
14. Antolini G, Pirani M, Morandi G, Sorio C. Differenze di genere e mortalità in una 
coorte di eroinomani nelle province emiliane di Modena e Ferrara [Gender 
difference and mortality in a cohort of heroin users in the Provinces of Modena 
and Ferrara, 1975–1999]. Epidemiol Prev 2006;30:91–9. PMID:16909957 

Prevalence of infections, HIV risk behaviors and factors associated with HIV 
infection among male injecting drug users attending a needle/syringe 
exchange program in Dhaka, Bangladesh. Subst Use Misuse 2008;43:2124–44. 
doi:10.1080/10826080802344583 PMID:19085439 
16. Azim T, Khan SI, Nahar Q, Reza M, Alam N, Saifi R, et al. 20 years of HIV in 
Bangladesh: experiences and way forward. Washington: World Bank; 2009. 

problem drug users in Rome: an 18-year follow-up study, 1980–97. Addiction 
2001;96:1455–63. doi:10.1046/j.1360-0443.2001.961014559.x PMID:11571064 



injection drug users in San Francisco: a 10-year follow-up of the UFO study. Am J 
Epidemiol 2012;175:302–8. doi:10.1093/aje/kwr318 PMID:22227793 
32. Ferri M, Bargagli AM, Faggiano F, Belleudi V, Salamina G, Vigna-Taglianti F 
et al. Gruppo di studio VEdeTTE. Mortalità in una coorte di tossicodipendenti 
da eroina arruolati presso i Ser.T in Italia, 1998–2001 [Mortality of drug users 
attending public treatment centers in Italy 1998–2001: a cohort study]. 
Epidemiol Prev 2007;31:276–82. PMID:18274231 

HIV-infected injection drug users in a primary care practice. J Addict Dis 
2006;25:33–8. doi:10.1300/J069v25n02_05 PMID:16785217 

cohort of drug injectors in Glasgow, 1982–1994. Addiction 1997;92:419–27. 
doi:10.1111/j.1360-0443.1997.tb03373.x PMID:9177063 

HIV-infected intravenous drug addicts in Stockholm in relation to methadone 
treatment. Addiction 1995;90:711–6. doi:10.1111/j.1360-0443.1995.tb02209.x 
PMID:7795507 

death among drug addicts in Stockholm during the period 1981–1992. Acta 
Psychiatr Scand 1997;96:169–75. doi:10.1111/j.1600-0447.1997.tb10147.x 
PMID:9296546 

opioid-maintained patients after release from an addiction clinic. Eur Addict Res 
2008;14:82–91. doi:10.1159/000113722 PMID:18334818 

37. Fugelstad A, Agren G, Romelsjö A. Changes in mortality, arrests, 
and hospitalizations in nonvoluntarily treated heroin addicts in 
relation to methadone treatment. Subst Use Misuse 1998;33:2803–17. 
doi:10.3109/10826089809059352 PMID:9869445 
di tossicodipendenti da eroina nel periodo 1985–1994 [Survival and mortality 
in a cohort of heroin addicts in 1985–1994]. Minerva Med 1995;86:97–9. 
PMID:7603612 

users living in Milan, Italy: role of HIV-1 infection. AIDS 1994;8:1457–63. 
doi:10.1097/00002030-199410000-00013 PMID:7818817 
20. Cardoso MN, Caiaffa WT, Mingoti SA. Projeto AjUDE-Brasil II. AIDS incidence 
and mortality in injecting drug users: the AjUDE-Brasil II Project. Cad 
Saude Publica 2006;22:827–37. doi:10.1590/S0102-311X2006000400021 
PMID:16612436 

tossicodipendenti nella Regione Emilia Romagna e i suoi determinanti. 
Risultati di uno studio longitudinale [Mortality risk in intravenous drug users in 
Emilia Romagna region and its socio-demographic determinants. Results of a 
longitudinal study]. Epidemiol Prev 2000;24:75–80. PMID:10863848 
22. Clausen T, Anchersen K, Waal H. Mortality prior to, during and after opioid 
maintenance treatment (OMT): a national prospective cross-registry study. 
Drug Alcohol Depend 2008;94:151–7. doi:10.1016/j.drugalcdep.2007.11.003 
PMID:18155364 
39. Goedert JJ, Pizza G, Gritti FM, Costigliola P, Boschini A, Bini A et al. Mortality 
among drug users in the AIDS era. Int J Epidemiol 1995;24:1204–10. 
doi:10.1093/ije/24.6.1204 PMID:8824864 
40. Goedert JJ, Fung MW, Felton S, Battjes RJ, Engels EA. Cause-specific mortality 
associated with HIV and HTLV-II infections among injecting drug users in 
the USA. AIDS 2001;15:1295–302. doi:10.1097/00002030-200107060-00012 
PMID:11426075 

antiretroviral therapy in IVDU and MSM – a retrospective study 1996-2000. 
Suchtmedizin in Forschung und Praxis. 2001;3:25–33. 
42. Haarr D, Nessa J. Opioidbehandling av rusmiddelavhengige i en allmennpraksis 
[Treatment of opiate-dependent patients in a general practice]. Tidsskr Nor 
Laegeforen 2007;127:1770–2. PMID:17599124 




Drug-related mortality and fatal overdose risk: pilot cohort study of heroin 
users recruited from specialist drug treatment sites in London. J Urban Health 
2003;80:274–87. doi:10.1093/jurban/jtg030 PMID:12791803 

study of drug users in Southern Iran. Addict Res Theory 2010;18:59–70. 
doi:10.3109/16066350902825930 
45. Jarrin I, Lumbreras B, Ferreros I, Pérez-Hoyos S, Hurtado I, Hernández-Aguado 
I. Effect of education on overall and cause-specific mortality in injecting 
drug users, according to HIV and introduction of HAART. Int J Epidemiol 
2007;36:187–94. doi:10.1093/ije/dyl231 PMID:17085455 

Republic. J Drug Issues 2007;37:103–18. doi:10.1177/002204260703700105 
47. Liu EW, Wang SJ, Liu Y, Liu W, Chen ZS, Li XY et al. Mortality of HIV infected 
clients treated with methadone maintenance treatment in Yili Kazakh 
autonomous prefecture. Zhonghua Yu Fang Yi Xue Za Zhi 2011;45:979–84. 
InChinese PMID:22336271 
48. Lumbreras B, Jarrín I, del Amo J, Pérez-Hoyos S, Muga R, García-de la Hera 
M et al. Impact of hepatitis C infection on long-term mortality of injecting 
drug users from 1990 to 2002: differences before and after HAART. AIDS 
2006;20:111–6. doi:10.1097/01.aids.0000196164.71388.3b PMID:16327326 
49. Manfredi R, Sabbatani S, Agostini D. Trend of mortality observed in a cohort of 
drug addicts of the metropolitan area of Bologna, North-Eastern Italy, during a 
25-year-period. Coll Antropol 2006;30:479–88. PMID:17058511 
50. McAnulty JM, Tesselaar H, Fleming DW. Mortality among injection drug 
users identified as “out of treatment”. Am J Public Health 1995;85:119–20. 
doi:10.2105/AJPH.85.1.119 PMID:7832249 

DC. A multicentre study on the causes of death among Italian injecting drug 
users. AIDS has overtaken overdose as the principal cause of death. AIDS Care 
1998;10:61–7. doi:10.1080/713612356 PMID:9536202 
52. Miller CL, Kerr T, Strathdee SA, Li K, Wood E. Factors associated with premature 
mortality among young injection drug users in Vancouver. Harm Reduct J 
2007;4:1. doi:10.1186/1477-7517-4-1 PMID:17201933 
53. Moroni M, Galli M. Causes of death in a cohort of intravenous-drug-users 
(IVDUs) recruited in Milan. AIDS Res Hum Retroviruses 1991;7:241–2. 
54. Moskalewicz J, Sierosławski J. Umieralność osób uzaleznionych od narkotyków 
przyjmowanych w iniekcjach [Mortality of narcotic addicts using injections]. 
Przegl Epidemiol 1996;50:323–32. InPolish PMID:8927745 
55. Muga R, Langohr K, Tor J, Sanvisens A, Serra I, Rey-Joly C et al. Survival of HIV- 
infected injection drug users (IDUs) in the highly active antiretroviral therapy 
era, relative to sex- and age-specific survival of HIV-uninfected IDUs. Clin Infect 
Dis 2007;45:370–6. doi:10.1086/519385 PMID:17599317 
56. Nyhlén A, Fridell M, Bäckström M, Hesse M, Krantz P. Substance abuse and 
psychiatric co-morbidity as predictors of premature mortality in Swedish 
drug abusers: a prospective longitudinal study 1970–2006. BMC Psychiatry 
2011;11:122–31. doi:10.1186/1471-244X-11-122 PMID:21801441 
57. O’Driscoll PT, McGough J, Hagan H, Thiede H, Critchlow C, Alexander ER. 
Predictors of accidental fatal drug overdose among a cohort of injection 
drug users. Am J Public Health 2001;91:984–7. doi:10.2105/AJPH.91.6.984 
PMID:11392946 
Systematic reviews 
Mortality among people who inject drugs 
65. Solomon SS, Celentano DD, Srikrishnan AK, Vasudevan CK, Anand S, Kumar MS 
et al. Mortality among injection drug users in Chennai, India (2005–2008). AIDS 
2009;23:997–1004. doi:10.1097/QAD.0b013e32832a594e PMID:19367155 
66. Sørensen HJ, Jepsen PW, Haastrup S, Juel K. Drug-use pattern, comorbid 
psychosis and mortality in people with a history of opioid addiction. Acta 
Psychiatr Scand 2005;111:244–9. doi:10.1111/j.1600-0447.2004.00445.x 
PMID:15701109 
67. Stenbacka M, Leifman A, Romelsjo A. Mortality among opiate abusers in 
Stockholm: a longitudinal study. Heroin Addict Rel Clin Prob 2007;9:41–9. 

drug users in Melbourne: a 16-year follow-up of the Victorian Injecting 
Cohort Study (VICS). Drug Alcohol Depend 2008;96:281–5. doi:10.1016/j. 
drugalcdep.2008.03.006 PMID:18434044 

implant or methadone maintenance treatment. J Subst Abuse Treat 
2008;35:116–24. doi:10.1016/j.jsat.2007.08.014 PMID:17931824 
70. van Haastrecht HJA, van Ameijden EJC, van den Hoek JAR, Mientjes GHC, 
Bax JS, Coutinho RA. Predictors of mortality in the Amsterdam cohort of 
human immunodeficiency virus (HIV)-positive and HIV-negative drug users. 
Am J Epidemiol 1996;143:380–91. doi:10.1093/oxfordjournals.aje.a008752 
PMID:8633622 
71. Vlahov D, Galai N, Safaeian M, Galea S, Kirk GD, Lucas GM et al. Effectiveness of 
highly active antiretroviral therapy among injection drug users with late-stage 
human immunodeficiency virus infection. Am J Epidemiol 2005;161:999–1012. 
doi:10.1093/aje/kwi133 PMID:15901620 

Collaborative Injection Drug User Study. Mortality risk among recent-onset 
injection drug users in five US cities. Subst Use Misuse 2008;43:413–28. 
doi:10.1080/10826080701203013 PMID:18365941 
73. Zábranský T, Csémy L, Grohmannová K, Janíková B, Brenza J. Mortality of cohort 
of very young injecting drug users in Prague, 1996–2010. Cent Eur J Public 
Health 2011;19:152–7. PMID:22026292 
74. Zaccarelli M, Gattari P, Rezza G, Conti S, Spizzichino L, Vlahov D et al. Impact of 
HIV infection on non-AIDS mortality among Italian injecting drug users. AIDS 
1994;8:345–50. doi:10.1097/00002030-199403000-00008 PMID:8031512 
75. Zhang L, Ruan YH, Jiang ZQ, Yang ZN, Liu SZ, Zhou F et al. [A 1-year prospective 
cohort study on mortality of injecting drug users]. Zhonghua Liu Xing Bing Xue 
Za Zhi 2005;26:190–3. PMID:15941506 
76. Mathers BM, Degenhardt L, Phillips B, Wiessing L, Hickman M, Strathdee 
SA. Reference Group to the UN on HIV and Injecting Drug Use. Global 
epidemiology of injecting drug use and HIV among people who inject 
drugs: a systematic review. Lancet 2008;372:1733–45. doi:10.1016/S0140- 
6736(08)61311-2 PMID:18817968 

Reference Group to the UN on HIV and Injecting Drug Use. HIV prevention, 
treatment and care for people who inject drugs: A systematic review of global, 
regional and country level coverage. Lancet 2010;375:1014–28. doi:10.1016/ 
S0140-6736(10)60232-2 PMID:20189638 
78. Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance versus no 
opioid replacement therapy for opioid dependence. Cochrane Database Syst 
Rev 2009;3:CD002209. PMID:19588333 


of heroin addicts from London clinics: a 22-year follow-up study. Addiction 
1994;89:1299–308. doi:10.1111/j.1360-0443.1994.tb03309.x PMID:7804091 
59. Quan VM, Vongchak T, Jittiwutikarn J, Kawichai S, Srirak N, Wiboonnatakul K 
AIDS. In: Twenty-sixth special session of the General Assembly of the United 
Nations. 25-27 June 2001. New York, United States of America; 2001. 
80. Mathers BM, Degenhardt L, Phillips B, Wiessing L, Hickman M, Strathdee 
et al. Predictors of mortality among injecting and non-injecting HIV-negative 
drug users in northern Thailand. Addiction 2007;102:441–6. doi:10.1111/j.1360- 
0443.2006.01709.x PMID:17298652 
60. Quan VM, Minh NL, Ha TV, Ngoc NP, Vu PT, Celentano DD et al. Mortality and 
HIV transmission among male Vietnamese injection drug users. Addiction 
2011;106:583–9. doi:10.1111/j.1360-0443.2010.03175.x PMID:21054619 
61. Rahimi-Movahgar A, Khastoo G, Razzaghi EM, Saberi-Zafarghandi MB, Noroozi 
AR, Jar-Siah R. Compulsory methadone maintenance treatment of severe cases 
of drug addiction in a residential setting in Tehran, Iran: outcome evaluation in 
two and six-month follow-up. Payesh 2011;10:503–12. 

addiction. J Addict Dis 2010;29:30–50. doi:10.1080/10550880903435988 
PMID:20390697 

heroin addicts in Catalonia: the EMETYST project. Addiction 2000;95:941–8. 
doi:10.1046/j.1360-0443.2000.95694110.x PMID:10946442 
64. Seaman SR, Brettle RP, Gore SM. Mortality from overdose among injecting 
drug users recently released from prison: database linkage study. BMJ 
1998;316:426–8. doi:10.1136/bmj.316.7129.426 PMID:9492665 
SA et al. Reference Group to the UN on HIV and Injecting Drug Use. Global 
epidemiology of injecting drug use and HIV among people who inject 
drugs: a systematic review. Lancet 2008;372:1733–45. doi:10.1016/S0140- 
6736(08)61311-2 PMID:18817968 

Evidence for the effectiveness of sterile injecting equipment provision 
in preventing hepatitis C and HIV transmission among injecting drug 
users: a review of reviews. Addiction 2010;105:844–59. doi:10.1111/j.1360- 
0443.2009.02888.x PMID:20219055 
82. Tilson H, Aramrattana A, Bozzette S. Preventing HIV infection among injecting 
drug users in high-risk countries: an assessment of the evidence. Washington: 
Institute of Medicine; 2007. 

Prevention of HIV infection for people who inject drugs: Why individual, 
structural, and combination approaches are required. Lancet 2010;376:285– 
301. doi:10.1016/S0140-6736(10)60742-8 PMID:20650522 
84. Baca CT, Grant KJ. Take-home naloxone to reduce heroin death. Addiction 
2005;100:1823–31. doi:10.1111/j.1360-0443.2005.01259.x PMID:16367983 




